Milind Javle, M.D.

Peer-Reviewed Articles

1. Limaye, SA, Shreenivas, A, Patil, D, Vyas, S, George, IA, Sambath, J, Singh, S, Madre, C, Parab, A, Kataria, P, Shah, D, Shah, N, Dawood, S, Rohatgi, N, Deshpande, R, Datta, A, Shamsi, HA, Gaya, A, Vaid, AK, Kulkarni, S, Rajappa, SJ, Rieke, D, Kumar, P, Datar, R, Javle, M. Actionable genomic landscape of biliary tract cancer in the Indian population. Oncologist 31(3), 2026. e-Pub 2026. PMID: 41520156.
2. Wang, X, Haro-Silerio, JI, Beaudry, FE, Borgida, A, Abbas-Aghababazadeh, F, Sahebi, NB, Wang, M, Fox, DA, Nuh, M, Hsiang, M, Bhamidipati, D, Kang, H, Cox, V, Ludmir, EB, Koay, EJ, Kwong, L, Quentin, K, Chatterjee, D, Chun, YS, Cao, HT, Meric-Bernstam, F, Hu, I, Dodd, A, Hamza, O, Hildebrand, M, Bucur, R, Hirschfield, GM, Vogel, A, O'Kane, GM, Gallinger, S, Haibe-Kains, B, Notta, F, Sapisochin, G, Knox, J, Javle, M, Lee, SS, Grant, RC. Clinicogenomic Characterization of Primary Sclerosing Cholangitis–Associated Biliary Tract Cancers. Clinical Cancer Research 32(2):363-374, 2026. e-Pub 2026. PMID: 41252561.
3. Saj, F, Namayanja, F, Xiao, L, Borad, MJ, Kelley, RK, Goyal, L, Azad, N, Bachini, M, Lindsey, S, Pant, S, Valle, JW, Fashoyin-Aje, L, Javle, M. Broadening the gates. Cancer 132(1), 2026. e-Pub 2026. PMID: 41417596.
4. Suryavanshi, M, Ostwal, V, Javle, M, Kumar, M, Shetty, O, Patil, D, Sharma, S, Limaye, SA, Patel, A, Sirohi, B, Bahl, A, Rohtagi, N. Genomic Profiling of Indian Gallbladder Carcinoma. JCO Global Oncology 11, 2025. e-Pub 2025. PMID: 41418080.
5. De, BS, Dogra, P, Zaid, M, Elganainy, D, Sun, K, Amer, A, Wang, CX, Rooney, M, Chang, E, Kang, H, Wang, Z, Bhosale, PR, Odisio, BC, Newhook, TE, Tzeng, CD, Tran Cao, HS, Chun, YS, Vauthey, JN, Lee, SS, Kaseb, A, Raghav, KS, Javle, M, Minsky, B, Noticewala, SS, Holliday, EB, Smith, GL, Koong, AC, Das, P, Cristini, V, Ludmir, EB, Koay, EJ. Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response. npj Systems Biology and Applications 11(1), 2025. e-Pub 2025. PMID: 41387975.
6. Verma, S, Hughes, A, Engel-Nitz, NM, Steiger, C, Parasuraman, S, Javle, M, Lee, SS, Saj, F, Blecker, M. Economic and clinical outcomes among patients with cholangiocarcinoma receiving pemigatinib with or without history of cancer of unknown primary. Oncologist 30(11), 2025. e-Pub 2025. PMID: 41148042.
7. Zhu, Y, Solis Soto, LM, Pant, S, Vega, EA, Vinuela, E, Bozorgui, B, Vauthey, JN, Aguayo, G, Wang, Z, Lu, W, Chen, X, Mino, B, Kakarala, L, Dai, J, Liu, S, Wani, K, Lazar, A, Carapeto, F, Lee, S, Wistuba, II, Korkut, A, Javle, M, Kwong, L. Population-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic Significance. Modern Pathology 38(11), 2025. e-Pub 2025. PMID: 40541865.
8. Dharia, A, Xiao, L, Abraham, J, Saj, F, Eluri, M, Hu, Z, Lee, SS, Hassan, MM, Muddassir, S, Javle, M. Ethnic and socioeconomic disparities in survival outcomes among patients under 65 years with intrahepatic cholangiocarcinoma. Journal of Gastrointestinal Oncology 16(5):2138-2145, 2025. e-Pub 2025.
9. Asif, A, Asif, A, Rooney, M, Chang, E, Namayanja, F, Quentin, K, Lee, S, Hu, I, Bernard-Pagan, V, Das, P, Holiday, EB, Noticewala, SS, Smith, GL, Koong, A, Ludmir, EB, Javle, M, Xiao, L, Koay, EJ. Safety and efficacy of liver-directed radiotherapy after chemoimmunotherapy for advanced cholangiocarcinoma. Journal of Gastrointestinal Oncology 16(5):2146-2157, 2025. e-Pub 2025.
10. Saj, F, Namayanja, F, Borad, MJ, Kelley, RK, Goyal, L, Azad, N, Bachini, M, Lindsey, S, Valle, JW, Fashoyin-Aje, L, Javle, M. Broadening the gates. Journal of Clinical Oncology 43:e23011-e23011, 2025. e-Pub 2025.
11. Valle, JW, Abou-Alfa, GK, Kelley, RK, Lowery, M, Shroff, R, Bian, Y, Saint-Hilary, G, Liu, H, Teng, Z, Hua, Z, Gliser, C, Vogel, A, Javle, M. Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma. ESMO Gastrointestinal Oncology 8, 2025. e-Pub 2025.
12. Jain, AJ, Lendoire, M, Haddad, A, Tzeng, CD, Boyev, A, Maki, H, Chun, YS, Arvide, EM, Lee, S, Hu, I, Pant, S, Javle, M, Tran Cao, HS, Vauthey, JN, Newhook, TE. Improved Outcomes Following Resection of Perihilar Cholangiocarcinoma. Annals of surgical oncology 32(6):4352-4362, 2025. e-Pub 2025. PMID: 40000564.
13. Kodali, S, Kulik, L, D'Allessio, A, De Martin, E, Hakeem, AR, Lewinska, M, Lindsey, S, Liu, K, Maravic, Z, Patel, MS, Pinato, DJ, Rammohan, A, Rich, NE, Sanduzzi Zamparelli, M, Victor, DW, Vinaxia, C, Brombosz, EW, Villanueva, A, Meyer, T, Selzner, N, Ghobrial, RM, Rela, M, Sapisochin, G, Abdelrahim, M, Agopian, VG, Balci, D, Bruix, J, Bekaii-Saab, T, Berenguer, M, Bhangui, P, Bhoori, S, Chan, AC, Chan, SL, Chieh, AW, Durand, F, Eghtesad, B, Elsabbagh, A, Halazun, KJ, Javle, M, Hibi, T, Jung, DH, Khalili, K, Lee, JM, Lewandowski, RJ, Line, PD, Llovet, JM, Mazzaferro, V, Mas, VR, Mehta, N, Morement, H, O'Kane, GM, Paradis, V, Parikh, ND, Pillai, A, Polak, W, Pomposelli, J, Rimassa, L, Singal, AG, Soin, AS, Tabrizian, P, Toso, C, Valle, JW, Vibert, E, Vogel, A, Rossi, JZ, Watt, KD, Woods, AW. The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma. Liver Transplantation 31(6):815-831, 2025. e-Pub 2025. PMID: 40014003.
14. Jain, AJ, Lendoire, M, Haddad, A, Tzeng, CD, Boyev, A, Maki, H, Chun, YS, Arvide, EM, Lee, S, Hu, I, Pant, S, Javle, M, Tran Cao, HS, Vauthey, JN, Newhook, TE. ASO Visual Abstract. Annals of surgical oncology 32(6):4445-4446, 2025. e-Pub 2025. PMID: 40131623.
15. Odisio, BC, Albuquerque, J, Lin, YM, Anderson, BM, OConnor, C, Rigaud, B, Briones-Dimayuga, M, Jones, AK, Fellman, B, Huang, SY, Kuban, JD, Metwalli, ZA, Sheth, RA, Habibollahi, P, Patel, MN, Shah, KY, Cox, V, Kang, HC, Morris, VK, Kopetz, S, Javle, M, Kaseb, A, Tzeng, CW, Cao, HT, Newhook, TE, Chun, YS, Vauthey, JN, Gupta, S, Paolucci, I, Brock, K. Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL). The Lancet Gastroenterology and Hepatology 10(5):442-451, 2025. e-Pub 2025. PMID: 40090348.
16. Goyal, L, DiToro, DF, Facchinetti, F, Martin, EE, Peng, P, Baiev, I, Iyer, R, Maurer, J, Reyes, S, Zhang, K, Majeed, U, Berchuck, JE, Chen, C, Walmsley, C, Pinto, C, Vasseur, D, Gordan, JD, Mody, K, Borad, MJ, Karasic, TB, Damjanov, N, Danysh, BP, Wehrenberg-Klee, E, Kambadakone, A, Saha, SK, Hoffman, I, Nelson, KJ, Iyer, S, Qiang, X, Sun, C, Wang, H, Li, L, Javle, M, Lin, B, Harris, WP, Zhu, AX, Cleary, JM, Flaherty, KT, Harris, T, Shroff, R, Leshchiner, I, Parida, L, Kelley, RK, Fan, J, Stone, JR, Uboha, NA, Hirai, H, Sootome, H, Wu, F, Bensen, DC, Hollebecque, A, Friboulet, L, Lennerz, JK, Getz, G, Juric, D. A model for decoding resistance in precision oncology. Annals of Oncology 36(4):426-443, 2025. e-Pub 2025. PMID: 39706336.
17. Grewal, K, Pant, S, Hu, I, Eluri, M, An, AW, Serpas Higbie, V, Huey, RW, Kasab, A, Javle, M, Lee, S. CLO25-099. Journal of the National Comprehensive Cancer Network : JNCCN 23(35), 2025. e-Pub 2025. PMID: 40154395.
18. Verma, S, Lee, SS, Blecker, M, Hughes, A, Engel-Nitz, NM, Parasuraman, S, Javle, M. HSR25-160. Journal of the National Comprehensive Cancer Network : JNCCN 23(35), 2025. e-Pub 2025. PMID: 40154361.
19. Ahmed, J, Knisely, A, Torrado, C, Stephen, B, Yang, Y, Song, J, Alshawa, A, Zarifa, A, Jhingran, A, Koay, EJ, Morris, VK, Javle, M, Wolff, RA, Meric-Bernstam, F, Pant, S, Rodon Ahnert, J, Naing, A. A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies. Oncologist 30(3), 2025. e-Pub 2025. PMID: 40139261.
20. Semaan, S, Connor, AA, Saharia, A, Kodali, S, Elaileh, A, Patel, K, Soliman, N, Basra, T, Victor, DW, Simon, CJ, Cheah, YL, Hobeika, MJ, Mobley, CM, Dhingra, S, Schwartz, MR, Maqsood, A, Heyne, K, Abdelrahim, M, Li, XC, Javle, M, Vauthey, JN, Gaber, AO, Ghobrial, RM. Transplantation for Peri-Hilar and Intrahepatic Cholangiocarcinoma With mTOR Immunosuppression. Transplantation proceedings 57(2):255-263, 2025. e-Pub 2025. PMID: 39939239.
21. Shroff, R, King, G, Colby, S, Scott, AJ, Borad, MJ, Goff, LW, Matin, K, Mahipal, A, Kalyan, A, Javle, M, El Dika, I, Tan, BR, Cheema, P, Patel, A, Iyer, R, Kelley, RK, Thumar, J, El-Khoueiry, AB, Guthrie, KA, Chiorean, EG, Hochster, HS, Philip, PA. SWOG S1815. Journal of Clinical Oncology 43(5):536-544, 2025. e-Pub 2025. PMID: 39671534.
22. Soliman, N, Connor, AA, Saharia, A, Kodali, S, Elaileh, A, Patel, K, Semaan, S, Basra, T, Victor, DW, Simon, CJ, Cheah, YL, Hobeika, MJ, Mobley, CM, Divatia, M, Dhingra, S, Schwartz, MR, Maqsood, A, Heyne, K, Abdelrahim, M, Javle, M, Vauthey, JN, Gaber, AO, Ghobrial, RM. Neoadjuvant Multiagent Systemic Therapy Approach to Liver Transplantation for Perihilar Cholangiocarcinoma. Transplantation Direct 11(3):e1760, 2025. e-Pub 2025. PMID: 39936132.
23. Seo, YD, Acidi, B, Newton, A, Haddad, A, Chiang, YJ, Coelho, R, Newhook, TE, Tzeng, CD, Chun, YS, Ludmir, EB, Koay, EJ, Javle, M, Vauthey, JN, Tran Cao, HS. Defining the Role of Adjuvant Radiotherapy for Biliary Tract Cancers. Cancers 17(3), 2025. e-Pub 2025. PMID: 39941861.
24. Naing, A, Mahipal, A, Javle, M, Wang, J, Bauer, TM, Bajor, D, Elias, A, Shields, AF, Davis, EJ, Chawla, SP, Safran, H, Powderly, J, D’amato, G, Meyer, C, Tang, X, Yao, S, Keegan, P. Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma. Journal of Immunotherapy and Precision Oncology 8(1):71-81, 2025. e-Pub 2025. PMID: 39816916.
25. DiPeri, TP, Evans, KW, Scott, S, Zheng, X, Varadarajan, K, Kwong, L, Kahle, M, Cao, HS, Tzeng, CW, Vu, T, Kim, S, Su, F, Raso, G, Rizvi, YQ, Zhao, M, Wang, H, Lee, SS, Yap, TA, Rodon Ahnert, J, Javle, M, Meric-Bernstam, F. Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. Clinical Cancer Research 31(2):387-402, 2025. e-Pub 2025. PMID: 39513959.
26. Hu, Z, Pavlick, D, Ross, JS, Lee, SS, Eluri, M, Javle, M. Molecular Profiling of Biliary Tract Cancers in African American and Caucasian Patients. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 39772832.
27. Javle, M. Updates in the Management of Biliary Tract Cancers. JNCCN Journal of the National Comprehensive Cancer Network 23, 2025. e-Pub 2025.
28. Abdelaal, MA, Diab, M, Farhat, MA, Javle, M, Shehata, MA, Singer, ED, Khamis, Y, Hassan, MM, Elsayes, KM, Szklaruk, J. Assessing the value of computed tomography (CT) of the chest in the follow-up of patients with intrahepatic cholangiocarcinoma. Journal of Gastrointestinal Oncology 15(6):2656-2662, 2024. e-Pub 2024. PMID: 39816039.
29. Piha-Paul, SA, Tseng, C, Leung, CH, Yuan, Y, Karp, DD, Subbiah, V, Hong, DS, Fu, S, Naing, A, Rodon Ahnert, J, Javle, M, Ajani, JA, Raghav, KS, Somaiah, N, Mills, GB, Tsimberidou, AM, Zheng, X, Chen, K, Meric-Bernstam, F. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 39085400.
30. Cox, V, Javle, M, Sun, J, Kang, H. Radiogenomics of Intrahepatic Cholangiocarcinoma. Journal of computer assisted tomography 48(6):868-874, 2024. e-Pub 2024. PMID: 38968316.
31. Cox, V, Javle, M, Sun, J, Kang, H. Radiogenomics of Intrahepatic Cholangiocarcinoma. Journal of computer assisted tomography 48(6):868-874, 2024. e-Pub 2024. PMID: 38968316.
32. Heumann, TR, Yarchoan, M, Murray, J, Lu, J, Li, D, Kunk, PR, Iyer, R, Dayyani, F, Kankeu Fonkoua, LA, Kalyan, A, Gbolahan, O, Javle, M, Davis, SL, Florou, V, Wright, J, Sharon, E, Wang, H, Lesinski, GB, Azad, N. A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer. Journal of Clinical Oncology 42(16):4017, 2024. e-Pub 2024.
33. Ngoi, NY, Tang, TY, Gaspar, CF, Pavlick, D, Buchold, G, Scholefield, EL, Parimi, V, Huang, RS, Janovitz, T, Danziger, N, Levy, M, Pant, S, De Armas, AD, Kumpula, D, Ross, JS, Javle, M, Rodon Ahnert, J. Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers. Oncologist 29(6):493-503, 2024. e-Pub 2024. PMID: 38330461.
34. DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, Dumbrava EE, Pant S, Ajani JA, Pohlmann PR, Jensen VB, Javle M, Rodon J, Meric-Bernstam F. Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov 14(5):828-845, 2024. e-Pub 2024. PMID: 38358339.
35. Jain AJ, Lendoire M, Boyev A, Newhook TE, Tzeng CD, Tran Cao HS, Coronel E, Lee SS, Hu ZI, Javle M, Lee JH, Vauthey JN, Chun YS. Revisiting the Malignant Masquerade at the Liver Hilum: Have We Made Progress?. Ann Surg Oncol 31(5):3062-3068, 2024. e-Pub 2024. PMID: 38282027.
36. Moffat GT, Hu ZI, Meric-Bernstam F, Kong EK, Pavlick D, Ross JS, Murugesan K, Kwong L, De Armas AD, Korkut A, Javle M, Knox JJ. KRAS Allelic Variants in Biliary Tract Cancers. JAMA Netw Open 7(5):e249840, 2024. e-Pub 2024. PMID: 38709532.
37. Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist 29(4):e514-e525, 2024. e-Pub 2024. PMID: 38297981.
38. Makawita, S, Lee, S, Kong, EK, Kwong, L, Abouelfetouh, Z, Danner De Armas, A, Xiao, L, Murugesan, K, Danziger, N, Pavlick, D, Korkut, A, Ross, JS, Javle, M. Comprehensive Immunogenomic Profiling of IDH1- / 2 -Altered Cholangiocarcinoma. JCO Precision Oncology 8, 2024. e-Pub 2024. PMID: 38547421.
39. Amaria, RN, Knisely, A, Vining, D, Kopetz, S, Overman, MJ, Javle, M, Antonoff, MB, Tzeng, CD, Wolff, RA, Pant, S, Lito, K, Rangel, KM, Fellman, B, Yuan, Y, Lu, KH, Sakellariou-Thompson, D, Haymaker, CL, Forget, MA, Hwu, P, Bernatchez, C, Jazaeri, AA. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. Journal for immunotherapy of cancer 12(2), 2024. e-Pub 2024. PMID: 38309721.
40. DiPeri TP, Zhao M, Evans KW, Varadarajan K, Moss T, Scott S, Kahle MP, Byrnes CC, Chen H, Lee SS, Halim AB, Hirai H, Wacheck V, Kwong LN, Rodon J, Javle M, Meric-Bernstam F. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol 80(2):322-334, 2024. e-Pub 2024. PMID: 37972659.
41. Nowlen, CJ, Daniels, MS, Uzunparmak, B, Ileana Dumbrava, EE, Yuan, Y, Patel, KP, Rayes, N, Harkenrider, J, Wathoo, C, Veazie, J, Luna, KA, Wang, W, Horombe, C, Javle, M, Rodon Ahnert, J, Yap, TA, Arun, BK, Lu, KH, Meric-Bernstam, F. Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. Journal of Immunotherapy and Precision Oncology 7(1):7-17, 2024. e-Pub 2024. PMID: 38327755.
42. Aranha, O, Javle, M, Rosales, M, Hu, Z, Faridi, AA, Paulson, S, Richards, DA, Hochster, HS, Cosgrove, D, Azad, N, Brown-Glaberman, UA, Cline, VM, Shumway, N, Tejani, MA, Nallapareddy, S, Sahin, I, Borad, MJ, Goyal, L, Kelley, RK. A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer. Journal of Clinical Oncology 42(3_suppl):TPS587-TPS587, 2024. e-Pub 2024.
43. Javle, M, Rimassa, L, Goyal, L, Mahipal, A, Fountzilas, C, Liao, CY, Pelster, MS, Mantry, P, Bridgewater, J, Hollebecque, A, Vandamme, T, Wyrwicz, L, Peng, P, Sun, C, Hennessy, K, Wang, H, Fu, X, Wu, F, Fan, J, Oh, DY. First-308. Journal of Clinical Oncology 42(3_suppl):TPS575-TPS575, 2024. e-Pub 2024.
44. Fox, DA, Haro-Silerio, JI, Bhamidipati, D, Meric-Bernstam, F, Pant, S, Ross, JS, Hu, Z, Koay, EJ, Ludmir, EB, Tran Cao, HS, Tzeng, CD, Chun, YS, Vauthey, JN, Newhook, TE, Metwalli, ZA, Habibollahi, P, Cox, V, Kang, H, Javle, M, Lee, SS. Characterizing outcomes of ERBB2-amplified biliary tract cancer. Journal of Clinical Oncology 42(3), 2024. e-Pub 2024.
45. Haro-Silerio, JI, Fox, DA, Bhamidipati, D, Hu, Z, Koay, EJ, Ludmir, EB, Tran Cao, HS, Vauthey, JN, Newhook, TE, Tzeng, CD, Chun, YS, Mahvash, A, Metwalli, ZA, Habibollahi, P, Cox, V, Kang, H, Chatterjee, D, Kaseb, A, Javle, M, Lee, SS. Characterization of outcomes and genomic alterations (GA) in combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA). Journal of Clinical Oncology 42(3):458, 2024. e-Pub 2024.
46. Lee, SS, Almhanna, K, Sheth, RA, Pant, S, Kuban, JD, Maxwell, A, Witt, BJ, LaPorte, J, Hulstine, AM, Cox, B, Carvajal, R, White, RA, Weintraub, J, Davis, L, Hart, J, Knight, RD, Katz, SC, Javle, M. PERIO-02. Journal of Clinical Oncology 42(16_suppl):2622, 2024. e-Pub 2024.
47. Wang, L, Singhal, M, Valderrama, A, Nepal, B, Kamble, S, Eluri, M, Malhotra, U, Siegel, AB, Grabner, M, Swami, S, Javle, M. Real-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA. Future Oncology 20(34):2625-2636, 2024. e-Pub 2024. PMID: 39155836.
48. Javle, M, Mahipal, A, Kankeu Fonkoua, LA, Fountzilas, C, Li, D, Pelster, MS, Liao, CY, Richards, DA, Deming, DA, Younes, MA, Mantry, P, Cohn, A, Kingsley, E, Fan, J, Peng, P, Sun, C, Wang, H, Hennessy, K, Shan, Y, Wu, F. Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma. Journal of Clinical Oncology 42(3), 2024. e-Pub 2024.
49. Abou-Alfa, GK, Borbath, I, Roychowdhury, S, Goyal, L, Lamarca, A, Macarulla, T, Shroff, R, Oh, DY, Javle, M, Tamas, C, Savastano, DM, van Veenhuyzen, D, Xu, C, Solanas, J, Freas, E. PROOF 301. Journal of Clinical Oncology 42(3):516, 2024. e-Pub 2024.
50. Zhu Y, Zhang D, Shukla P, Jung YH, Malgulwar PB, Chagani S, Colic M, Benjamin S, Copland Iii JA, Tan L, Lorenzi PL, Javle M, Huse JT, Roszik J, Hart T, Kwong LN. CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon. JCI Insight 9(2), 2024. e-Pub 2024. PMID: 38060314.
51. Nelson BE, Roszik J, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah V. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol 7(1):19, 2023. e-Pub 2023. PMID: 36801912.
52. Hatia RI, Eluri M, Hawk ET, Shalaby A, Karatas E, Shalaby A, Abdelhakeem A, Abdel-Wahab R, Chang P, Rashid A, Jalal PK, Amos CI, Han Y, Armaghany T, Shroff RT, Li D, Javle M, Hassan MM. Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity is Associated with Cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev 32(10):1338-1347, 2023. e-Pub 2023. PMID: 37540502.
53. Maithel SK, Keilson JM, Cao HST, Rupji M, Mahipal A, Lin BS, Javle MM, Cleary SP, Akce M, Switchenko JM, Rocha FG. ASO Visual Abstact: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma. Ann Surg Oncol 30(11):6569-6570, 2023. e-Pub 2023. PMID: 37368098.
54. Yoo C, Javle MM, Verdaguer Mata H, de Braud F, Trojan J, Raoul JL, Kim JW, Ueno M, Lee CK, Hijioka S, Cubillo A, Furuse J, Azad N, Sato M, Vugmeyster Y, Machl A, Bajars M, Bridgewater J, Oh DY, Borad MJ. Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers. Hepatology 78(3):758-770, 2023. e-Pub 2023. PMID: 36999533.
55. De B, Upadhyay R, Liao K, Kumala T, Shi C, Dodoo G, Abi Jaoude J, Corrigan KL, Manzar GS, Marqueen KE, Bernard V, Lee SS, Raghav KPS, Vauthey JN, Tzeng CD, Tran Cao HS, Lee G, Wo JY, Hong TS, Crane CH, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Javle M, Ludmir EB, Koay EJ. Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases. Liver Cancer 12(3):198-208, 2023. e-Pub 2023. PMID: 37593365.
56. Pappas L, Baiev I, Reyes S, Bocobo AG, Jain A, Spencer K, Le TM, Rahma OE, Maurer J, Stanton J, Zhang K, De Armas AD, Deleon TT, Roth M, Peters MLB, Zhu AX, Boyhen K, VanCott C, Patel T, Roberts LR, Lindsey S, Horick N, Lennerz JK, Iafrate AJ, Goff LW, Mody K, Borad MJ, Shroff RT, Javle MM, Kelley RK, Goyal L. The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma. JCO Precis Oncol 7:e2200594, 2023. e-Pub 2023. PMID: 37561981.
57. Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Boyken L, Ma J, Garfin P, Pant S, group HS. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol 24(7):772-782, 2023. e-Pub 2023. PMID: 37276871.
58. Ngo-Huang AT, Parker NH, Xiao L, Schadler KL, Petzel MQB, Prakash LR, Kim MP, Tzeng CD, Lee JE, Ikoma N, Wolff RA, Javle MM, Koay EJ, Pant SD, Folloder JP, Wang X, Cotto AM, Ju YR, Garg N, Wang H, Bruera ED, Basen-Engquist KM, Katz MHG. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized Clinical Trial. Ann Surg 278(1):22-30, 2023. e-Pub 2023. PMID: 37026453.
59. Spencer K, Pappas L, Baiev I, Maurer J, Bocobo AG, Zhang K, Jain A, De Armas AD, Reyes S, Le TM, Rahma OE, Stanton J, DeLeon TT, Roth M, Peters MLB, Zhu AX, Lennerz JK, Iafrate AJ, Boyhen K, VanCott C, Roberts LR, Lindsey S, Horick N, Goff LW, Mody K, Borad MJ, Shroff RT, Kelley RK, Javle MM, Goyal L. Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma. J Natl Cancer Inst 115(7):870-880, 2023. e-Pub 2023. PMID: 37040087.
60. Maithel SK, Keilson JM, Cao HST, Rupji M, Mahipal A, Lin BS, Javle MM, Cleary SP, Akce M, Switchenko JM, Rocha FG. NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. e-Pub 2023. PMID: 37368098.
61. Janku F, Javle MM, Sen S, Pant S, Bramwell LG, Subbiah V, Way T, Wages DS, Wheeler CA, Suzuki T, Saeki K, Subach RA, Madden T, Maier G, Johansen MJ, Cheung K, Falchook GS. A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors. Cancer 129(10):1537-1546, 2023. e-Pub 2023. PMID: 36882377.
62. Dodoo GN, De B, Lee SS, Abi Jaoude J, Vauthey JN, Tzeng CD, Tran Cao HS, Katlowitz KA, Mandel JJ, Beckham TH, Minsky BD, Smith GL, Holliday EB, Koong AC, Das P, Taniguchi CM, Javle M, Koay EJ, Ludmir EB. Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. Oncologist 28(4):327-332, 2023. e-Pub 2023. PMID: 36715178.
63. Ayabe RI, Paez-Arango N, Estrella JS, Newhook TE, Tzeng CD, Chun YS, Lee S, Javle M, Vauthey JN, Tran Cao HS. Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma - does pathologic response mean better outcomes?. HPB (Oxford) 25(4):472-480, 2023. e-Pub 2023. PMID: 36781357.
64. Tennison JM, Asher A, Hui D, Javle M, Bassett RL, Bruera E. Palliative Rehabilitation in Acute Inpatient Rehabilitation: Prognostic Factors and Functional Outcomes in Patients with Cancer. Oncologist 28(2):180-186, 2023. e-Pub 2023. PMID: 36367387.
65. Tang TY, Nichetti F, Kaplan B, Lonardi S, Pietrantonio F, Salvatore L, Vivaldi C, Rimassa L, de Braud F, Rizzato MD, Pavlick D, Chu R, Danner De Armas A, Sharaf R, Sokol E, Rodon Ahnert J, Ross JS, Javle M, Niger M. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers. Clin Cancer Res 29(23):4853-4862, 2023. e-Pub 2023. PMID: 37773629.
66. Berchuck JE, Facchinetti F, DiToro DF, Baiev I, Majeed U, Reyes S, Chen C, Zhang K, Sharman R, PLSU J, Maurer J, Shroff RT, Pritchard CC, Wu MJ, Catenacci DVT, Javle M, Friboulet L, Hollebecque A, Bardeesy N, Zhu AX, Lennerz JK, Tan B, Borad M, Parikh AR, Kiedrowski LA, Kelley RK, Mody K, Juric D, Goyal L. The Clinical Landscape of Cell-Free DNA Alterations in 1,671 Patients with Advanced Biliary Tract Cancer. Ann Oncol 33(12):1269-1283, 2022. e-Pub 2022. PMID: 36089135.
67. Koay EJ, Zaid M, Aliru M, Bagereka P, Van Wieren A, Rodriguez MJ, Jacobson G, Wolff RA, Overman M, Varadhachary G, Pant S, Wang H, Tzeng CW, Ikoma N, Kim M, Lee JE, Katz MH, Tamm E, Bhosale P, Taniguchi CM, Holliday EB, Smith GL, Ludmir EB, Minsky BD, Crane CH, Koong AC, Das P, Wang X, Javle M, Krishnan S. Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients with Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase I Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys 114(3):444-453, 2022. e-Pub 2022. PMID: 35863672.
68. Schalck A, Sakellariou-Thompson D, Forget MA, Sei E, Hughes TG, Reuben A, Bai S, Hu M, Kumar T, Hurd MW, Katz MHG, Tzeng CD, Pant S, Javle M, Fogelman DR, Maitra A, Haymaker CL, Kim MP, Navin NE, Bernatchez C. Single cell sequencing reveals trajectory of tumor-infiltrating lymphocyte states in pancreatic cancer. Cancer Discov 12(10):2330-2349, 2022. e-Pub 2022. PMID: 35849783.
69. Javle M, Lee S, Azad NS, Borad MJ, Kate Kelley R, Sivaraman S, Teschemaker A, Chopra I, Janjan N, Parasuraman S, Bekaii-Saab TS. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017. Oncologist 27(10):874-883, 2022. e-Pub 2022. PMID: 35972334.
70. Hester CA, Perri G, Prakash LR, Maxwell JE, Ikoma N, Kim MP, Tzeng CD, Smaglo B, Wolff R, Javle M, Overman MJ, Lee JE, Katz MHG. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. J Natl Compr Canc Netw 20(8):887-897.e3, 2022. e-Pub 2022. PMID: 35948035.
71. De B, Tran Cao HS, Vauthey JN, Manzar GS, Corrigan KL, Raghav KPS, Lee SS, Tzeng CD, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Javle M, Ludmir EB, Koay EJ. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer 128(13):2529-2539, 2022. e-Pub 2022. PMID: 35417569.
72. Lee S, Shroff RT, Makawita S, Xiao L, Danner De Armas A, Bhosale P, Reddy K, Shalaby A, Raghav K, Pant S, Wolff RA, Javle M. Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated by Gemcitabine-based Chemotherapy. Clin Cancer Res 28(11):2229-2236, 2022. e-Pub 2022. PMID: 35312753.
73. Silverman IM, Li M, Murugesan K, Krook MA, Javle MM, Kelley RK, Borad MJ, Roychowdhury S, Meng W, Yilmazel B, Milbury C, Shewale S, Feliz L, Burn TC, Albacker LA. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling. J Mol Diagn 24(4):351-364, 2022. e-Pub 2022. PMID: 35176488.
74. Manzar GS, De BS, Abana CO, Lee SS, Javle M, Kaseb AO, Vauthey JN, Tran Cao HS, Koong AC, Smith GL, Taniguchi CM, Holliday EB, Das P, Koay EJ, Ludmir EB. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers (Basel) 14(8), 2022. e-Pub 2022. PMID: 35454808.
75. McMillan RR, Javle M, Kodali S, Saharia A, Mobley C, Heyne K, Hobeika MJ, Lunsford KE, Victor DW, Shetty A, McFadden RS, Abdelrahim M, Kaseb A, Divatia M, Yu N, Nolte Fong J, Moore LW, Nguyen DT, Graviss EA, Gaber AO, Vauthey JN, Ghobrial RM. Survival following liver transplantation for locally-advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transplant 22(3):823-832, 2022. e-Pub 2022. PMID: 34856069.
76. Panettieri E, Maki H, Kim BJ, Kang HC, Cox V, Vega EA, Mizuno T, Pant S, Javle M, Vauthey JN, Kawaguchi Y. Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma. Surg Oncol 40:101696, 2022. e-Pub 2022. PMID: 34995974.
77. Javle, M, Oh, DY, Ikeda, M, Yong, WP, Hsu, K, Lindmark, B, McIntyre, N, Firth, C. Varlitinib plus capecitabine in second-line advanced biliary tract cancer. ESMO Open 7(1), 2022. e-Pub 2022. PMID: 34922298.
78. Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, Wistuba I, Meric-Bernstam F, Shalaby A, Javle M, Korkut A, Kwong LN. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology 75(2):297-308, 2022. e-Pub 2022. PMID: 34510503.
79. DiPeri TP, Demirhan M, Karp DD, Fu S, Hong DS, Subbiah V, Lim J, Ballester LY, Tayar JH, Suarez-Almazor ME, Javle M, Meric-Bernstam F. Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. J Immunother Precis Oncol 5(1):26-30, 2022. e-Pub 2022. PMID: 35663835.
80. Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, Tran B, Kelley RK, Park JO, Javle M, He Y, Benhadji KA, Goyal L. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study. Cancer Discov 12(2):402-415, 2022. e-Pub 2022. PMID: 34551969.
81. Lapin M, Huang HJ, Chagani S, Javle M, Shroff RT, Pant S, Gouda MA, Raina A, Madwani K, Holley VR, Call SG, Dustin DJ, Lanman RB, Meric-Bernstam F, Raymond VM, Kwong LN, Janku F. Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precis Oncol 6:e2100197, 2022. e-Pub 2022. PMID: 35171660.
82. Salcedo M, Vinaixa C, Javle M, Trapero-Marugán M, Bustamante J, Line PD. Evaluation and Management of Liver Transplant Candidates With Prior Nonhepatic Cancer: Guidelines From the ILTS/SETH Consensus Conference. Transplantation 106(1):e3-e11, 2022. e-Pub 2022. PMID: 34905758.
83. De B, Abu-Gheida I, Patel A, Ng SSW, Zaid M, Thunshelle CP, Elganainy D, Corrigan KL, Rooney MK, Javle M, Raghav K, Lee SS, Vauthey JN, Tzeng CD, Tran Cao HS, Ludmir EB, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Koay EJ. Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J Pers Med 11(12), 2021. e-Pub 2021. PMID: 34945742.
84. Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol 7(11):1669-1677, 2021. e-Pub 2021. PMID: 34554208.
85. Rogers JE, Mizrahi JD, Nogueras Gonzalez GM, Surana R, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Raghav K, Pant S. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. J Gastrointest Oncol 12(5):2268-2274, 2021. e-Pub 2021. PMID: 34790391.
86. Mason MC, Massarweh NN, Tzeng CD, Chiang YJ, Chun YS, Aloia TA, Javle M, Vauthey JN, Tran Cao HS. Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience. Ann Surg Oncol 28(11):6725-6735, 2021. e-Pub 2021. PMID: 33586068.
87. Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, Bekaii-Saab TS, Abou-Alfa GK. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 6(10):803-815, 2021. e-Pub 2021. PMID: 34358484.
88. Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 22(9):1290-1300, 2021. e-Pub 2021. PMID: 34339623.
89. Mohindroo C, Hasanov M, Rogers JE, Dong W, Prakash LR, Baydogan S, Mizrahi JD, Overman MJ, Varadhachary GR, Wolff RA, Javle MM, Fogelman DR, Lotze MT, Kim MP, Katz MHG, Pant S, Tzeng CD, McAllister F. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med 10(15):5041-5050, 2021. e-Pub 2021. PMID: 34250759.
90. Hui D, Puac V, Shelal Z, Liu D, Maddi R, Kaseb A, Javle M, Overman M, Yennurajalingam S, Gallagher C, Bruera E. Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial. J Pain Symptom Manage 62(2):223-232.e1, 2021. e-Pub 2021. PMID: 33388382.
91. Javle M, Shacham-Shmueli E, Xiao L, Varadhachary G, Halpern N, Fogelman D, Boursi B, Uruba S, Margalit O, Wolff RA, Golan T. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials. JAMA Oncol 7(5):693-699, 2021. e-Pub 2021. PMID: 33662100.
92. DiPeri TP, Javle MM, Meric-Bernstam F. Next generation sequencing for biliary tract cancers. Expert Rev Gastroenterol Hepatol 15(5):471-474, 2021. e-Pub 2021. PMID: 33641586.
93. Perri G, Prakash L, Wang H, Bhosale P, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay E, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg 273(4):806-813, 2021. e-Pub 2021. PMID: 31274655.
94. Lee SH, Simoneau EB, Karpinets T, Futreal PA, Zhang J, Javle M, Zhang J, Vauthey JN, Lee JS, Estrella JS, Chun YS. Genomic Profiling of Multifocal Intrahepatic Cholangiocarcinoma Reveals Intraindividual Concordance of Genetic Alterations. Carcinogenesis 42(3):436-441, 2021. e-Pub 2021. PMID: 33200197.
95. Hecht JR, Papadopoulos KP, Falchook GS, Patel MR, Infante JR, Aljumaily R, Wong DJ, Autio KA, Wainberg ZA, Bauer TM, Javle M, Pant S, Bendell J, Hung A, Ratti N, VanVlasselaer P, Verma R, Leveque J, Rao S, Oft M, Naing A. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Invest New Drugs 39(1):182-192, 2021. e-Pub 2021. PMID: 32910338.
96. Murugesan K, Sharaf R, Montesion M, Moore JA, Pao J, Pavlick DC, Frampton GM, Upadhyay VA, Alexander BM, Miller VA, Javle MM, Bekaii Saab TS, Albacker LA, Ross JS, Ali SM. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. JCO Precis Oncol 5:1285-1296, 2021. e-Pub 2021. PMID: 34476330.
97. Xu M, Tapia C, Hajjar J, Sabir S, Colen R, Nagarajan P, Aung PP, Gong J, Rodon J, Fu S, Stephen B, Roy-Chowdhuri S, Le H, Yang V, Zarifa A, Abdelsalam ME, Jhingran A, Javle M, Pant S, Carter B, Milton DR, Sun R, Karp DD, Koay EJ, Yang Y, Wistuba II, Hwu P, Meric-Bernstam F, Naing A. Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. J Immunother Precis Oncol 4(2):45-52, 2021. e-Pub 2021. PMID: 35663531.
98. Martin NA, Tepper JE, Giri VN, Stinchcombe TE, Cheng HH, Javle MM, Konnick EQ. Adopting Consensus Terms for Testing in Precision Medicine. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34651094.
99. Ajani JA, Javle M, Eng C, Fogelman D, Smith J, Anderson B, Zhang C, Iizuka K. Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Invest New Drugs 38(6):1763-1773, 2020. e-Pub 2020. PMID: 32377978.
100. Abdel-Wahab R, Yap TA, Madison R, Pant S, Cooke M, Wang K, Zhao H, Bekaii-Saab T, Karatas E, Kwong LN, Meric-Bernstam F, Borad M, Javle M. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep 10(1):22087, 2020. e-Pub 2020. PMID: 33328484.
101. Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, Pan BF, Lorenzi PL, Hurd M, Mittendorf EA, Peterson CB, Javle M, Bristow C, Kim M, Tuveson DA, Hawke D, Kopetz S, Wolff RA, Hwu P, Maitra A, Roszik J, Yee C, Lizée G. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nat Commun 11(1):5332, 2020. e-Pub 2020. PMID: 33087697.
102. Makawita S, K Abou-Alfa G, Roychowdhury S, Sadeghi S, Borbath I, Goyal L, Cohn A, Lamarca A, Oh DY, Macarulla T, T Shroff R, Howland M, Li A, Cho T, Pande A, Javle M. Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol 16(30):2375-2384, 2020. e-Pub 2020. PMID: 32580579.
103. Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, de Braud F, Prager GW, Greil R, Stein A, Fasolo A, Schellens JHM, Wen PY, Viele K, Boran AD, Gasal E, Burgess P, Ilankumaran P, Wainberg ZA. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 21(9):1234-1243, 2020. e-Pub 2020. PMID: 32818466.
104. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg 155(9):832-839, 2020. e-Pub 2020. PMID: 32667641.
105. Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Fogelman DR, Raghav KPS, Pant S, McAllister F. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med 9(15):5406-5415, 2020. e-Pub 2020. PMID: 32519420.
106. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg 271(6):996-1002, 2020. e-Pub 2020. PMID: 31895709.
107. Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21(6):796-807, 2020. e-Pub 2020. PMID: 32416072.
108. Kim RD, McDonough S, El-Khoueiry AB, Bekaii-Saab TS, Stein SM, Sahai V, Keogh GP, Kim EJ, Baron AD, Siegel AB, Barzi A, Guthrie KA, Javle M, Hochster H. Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer. Eur J Cancer 130:219-227, 2020. e-Pub 2020. PMID: 32234665.
109. Pairawan S, Hess KR, Janku F, Sanchez NS, Mills Shaw KR, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-Free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res 26(8):1924-1931, 2020. e-Pub 2020. PMID: 31852833.
110. Mizrahi JD, Rogers JE, Hess KR, Wolff RA, Varadhachary GR, Javle MM, Shroff RT, Ho L, Fogelman DR, Raghav KPS, Overman MJ, Pant S. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology 20(3):501-504, 2020. e-Pub 2020. PMID: 31932214.
111. Goldstein JB, Zhao L, Wang X, Ghelman Y, Overman MJ, Javle MM, Shroff RT, Varadhachary GR, Wolff RA, McAllister F, Futreal A, Fogelman DR. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Pancreatic Cancer Patients. Clin Cancer Res 26(6):1385-1394, 2020. e-Pub 2020. PMID: 31871297.
112. Rogers JE, Mizrahi JD, Shroff RT, Nelson DA, Tu J, Javle MM, Wolff RA, Pant S. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. J Gastrointest Oncol 11(1):55-60, 2020. e-Pub 2020. PMID: 32175105.
113. Overman M, Javle M, Davis RE, Vats P, Kumar-Sinha C, Xiao L, Mettu NB, Parra ER, Benson AB, Lopez CD, Munugalavadla V, Patel P, Tao L, Neelapu S, Maitra A. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32114502.
114. Javle M. On the cusp of a sea change in biliary tract cancer. Chin Clin Oncol 9(1):1, 2020. e-Pub 2020. PMID: 32075398.
115. Cao J, Hu J, Liu S, Meric-Bernstam F, Abdel-Wahab R, Xu J, Li Q, Yan M, Feng Y, Lin J, Zhao S, Wang J, Kwong LN, Hu J, Carapeto F, Borad MJ, Wang K, Javle M, Zhao H. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. JCO Precis Oncol 4, 2020. e-Pub 2020. PMID: 32923885.
116. Yang P, Javle M, Pang F, Zhao W, Abdel-Wahab R, Chen X, Meric-Bernstam F, Chen H, Borad MJ, Liu Y, Zou C, Mu S, Xing Y, Wang K, Peng C, Che X. Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surg Nutr 8(6):604-614, 2019. e-Pub 2019. PMID: 31929987.
117. Javle M, Zhao H, Abou-Alfa GK. Systemic therapy for gallbladder cancer. Chin Clin Oncol 8(4):44, 2019. e-Pub 2019. PMID: 31484490.
118. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol 5(6):824-830, 2019. e-Pub 2019. PMID: 30998813.
119. Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, Crane CH, Das P, Herman JM, Koay EJ, Taniguchi C, Holliday EB, Minsky BD, Suh Y, Park P, Sawakuchi G, Beddar S, Odisio BC, Gupta S, Loyer E, Kaur H, Raghav K, Javle MM, Kaseb AO, Krishnan S. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol 133:54-61, 2019. e-Pub 2019. PMID: 30935582.
120. Gulhati P, Prakash L, Katz MHG, Wang X, Javle M, Shroff R, Fogelman D, Lee JE, Tzeng CD, Lee JH, Weston B, Tamm E, Bhosale P, Koay EJ, Maitra A, Wang H, Wolff RA, Varadhachary GR. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 26(2):619-627, 2019. e-Pub 2019. PMID: 30324485.
121. Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies. Cancer 125(3):463-472, 2019. e-Pub 2019. PMID: 30383888.
122. Odisio BC, Krampitz GW, Murthy R, Mahvash A, Javle M, Vauthey JN. Preoperative drainage for perihilar cholangiocarcinoma. Lancet Gastroenterol Hepatol 4(1):10-11, 2019. e-Pub 2019. PMID: 30527574.
123. Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, Stephens BM, Huang J, Semaan A, Guerrero PA, Kamyabi N, Zhao J, Hurd MW, Koay EJ, Taniguchi CM, Herman JM, Javle M, Wolff R, Katz M, Varadhachary G, Maitra A, Alvarez HA. Circulating Nucleic Acids Associate with Outcomes of Patients with Pancreatic Cancer. Gastroenterology 156(1):108-118.e4, 2019. e-Pub 2019. PMID: 30240661.
124. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32923865.
125. Koay EJ, Katz MHG, Wang H, Wang X, Prakash L, Javle M, Shroff R, Fogelman D, Avila S, Zaid M, Elganainy D, Lee Y, Crane CH, Krishnan S, Das P, Fleming JB, Lee JE, Tamm EP, Bhosale P, Lee JH, Weston B, Maitra A, Wolff RA, Varadhachary GR. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32914036.
126. Finn RS, Ahn DH, Javle MM, Tan BR, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Chavira R, Christy-Bittel J, Barrett E, Sawyer MB, Bekaii-Saab TS. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Invest New Drugs 36(6):1037-1043, 2018. e-Pub 2018. PMID: 29785570.
127. Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas FAS, Hobbs BP, Ye R, Elganainy D, Almahariq M, Amer AM, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss KA, Yu S, Chauhan A, Zaid M, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MH, Wang H, Bhosale P, Tamm EP, Fleming JB. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24(23):5883-5894, 2018. e-Pub 2018. PMID: 30082477.
128. Lapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H, Javle M, Glenjen NI, Abelseth BK, Gilje B, Nordgård O. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. J Transl Med 16(1):300, 2018. e-Pub 2018. PMID: 30400802.
129. Fountzilas C, Javle M, Tan W, Ma Y, Fetterly G, Iyer R, Johnson C. A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. Cancer 124(19):3890-3899, 2018. e-Pub 2018. PMID: 30299542.
130. Elganainy D, Holliday EB, Taniguchi CM, Smith GL, Shroff R, Javle M, Raghav K, Kaseb A, Aloia TA, Vauthey JN, Tzeng CD, Herman JM, Koong AC, Krishnan SX, Minsky BD, Crane CH, Das P, Koay EJ. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med 7(10):4880-4892, 2018. e-Pub 2018. PMID: 30152073.
131. Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, Stephens BM, Huang J, Semaan A, Guerrero PA, Kamyabi N, Zhao J, Hurd MW, Koay EJ, Taniguchi CM, Herman JM, Javle M, Wolff R, Katz M, Varadhachary G, Maitra A, Alvarez HA. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology, 2018. e-Pub 2018. PMID: 30240661.
132. Lunsford KE, Javle M, Gaber AO, Vauthey JN, Ghobrial RM. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma - Authors' reply. Lancet Gastroenterol Hepatol 3(8):529-530, 2018. e-Pub 2018. PMID: 30047444.
133. Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother 41(6):284-291, 2018. e-Pub 2018. PMID: 29668571.
134. Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther 17(7):1595-1601, 2018. e-Pub 2018. PMID: 29654067.
135. Sheth RA, Sabir SH, Parmet P, Amin R, Kuban JD, Huang SY, Mahvash A, Fogelman D, Javle M, Wallace MJ. Portomesenteric Venous Stenting for Palliation of Ascites and Variceal Bleeding Caused by Prehepatic Portal Hypertension. Oncologist 23(6):712-718, 2018. e-Pub 2018. PMID: 29284759.
136. Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, Kaseb AO, McFadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey JN, Ghobrial RM, Collaborative Committee MAJC. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol 3(5):337-348, 2018. e-Pub 2018. PMID: 29548617.
137. Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, Overman MJ, Wolff RA, Javle M. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol 11(1):71, 2018. e-Pub 2018. PMID: 29843755.
138. Wang YN, Lee HH, Chou CK, Yang WH, Wei Y, Chen CT, Yao J, Hsu JL, Zhu C, Ying H, Ye Y, Wang WJ, Lim SO, Xia W, Ko HW, Liu X, Liu CG, Wu X, Wang H, Li D, Prakash LR, Katz MH, Kang Y, Kim M, Fleming JB, Fogelman D, Javle M, Maitra A, Hung MC. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell 33(4):752-769.e8, 2018. e-Pub 2018. PMID: 29606349.
139. Gulhati P, Raghav K, Shroff R, Varadhachary G, Javle M, Qiao W, Wang H, Morris J, Wolff R, Overman MJ. Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist 23(3):277-e26, 2018. e-Pub 2018. PMID: 29259073.
140. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol 36(3):JCO2017755009, 2018. e-Pub 2018. PMID: 29182496.
141. Castillo J, Bernard V, San Lucas FA, Allenson K, Capello M, Kim DU, Gascoyne P, Mulu FC, Stephens BM, Huang J, Wang H, Momin AA, Jacamo RO, Katz M, Wolff R, Javle M, Varadhachary G, Wistuba II, Hanash S, Maitra A, Alvarez H. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Ann Oncol 29(1):223-229, 2018. e-Pub 2018. PMID: 29045505.
142. Sakellariou-Thompson D, Forget MA, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary G, Javle M, Overman MJ, Alvarez HA, Heffernan TP, Zhang J, Hwu P, Maitra A, Haymaker C, Bernatchez C. 4-1BB Agonist Focuses CD8(+) Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Clin Cancer Res 23(23):7263-7275, 2017. e-Pub 2017. PMID: 28947567.
143. Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg 152(11):1048-1056, 2017. e-Pub 2017. PMID: 28700784.
144. Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 15(11):1791-1799, 2017. e-Pub 2017. PMID: 28579181.
145. Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget 8(50):87163-87173, 2017. e-Pub 2017. PMID: 29152071.
146. Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res 23(18):5648-5656, 2017. e-Pub 2017. PMID: 28536309.
147. Cloyd JM, Wang H, Overman M, Zhao J, Denbo J, Prakash L, Kim MP, Shroff R, Javle M, Varadhachary GR, Fogelman D, Wolff RA, Koay EJ, Das P, Maitra A, Aloia TA, Vauthey JN, Fleming JB, Lee JE, Katz MHG. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol 24(7):2031-2039, 2017. e-Pub 2017. PMID: 28124275.
148. Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer 123(6):1011-1017, 2017. e-Pub 2017. PMID: 27859010.
149. Lapin M, Tjensvoll K, Oltedal S, Javle M, Smaaland R, Gilje B, Nordgård O. Single-cell mRNA profiling reveals transcriptional heterogeneity among pancreatic circulating tumour cells. BMC Cancer 17(1):390, 2017. e-Pub 2017. PMID: 28569190.
150. Yamashita S, Koay EJ, Passot G, Shroff R, Raghav KP, Conrad C, Chun YS, Aloia TA, Tao R, Kaseb A, Javle M, Crane CH, Vauthey JN. Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. Cancer 123(8):1354-1362, 2017. e-Pub 2017. PMID: 27984655.
151. Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Br J Cancer 116(6):697-702, 2017. e-Pub 2017. PMID: 28183138.
152. Yamashita S, Passot G, Aloia TA, Chun YS, Javle M, Lee JE, Vauthey JN, Conrad C. Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer. Br J Surg 104(3):267-277, 2017. e-Pub 2017. PMID: 28052308.
153. Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer 116(5):575-583, 2017. e-Pub 2017. PMID: 28152546.
154. Chadha AS, Liu G, Chen HC, Das P, Minsky BD, Mahmood U, Delclos ME, Suh Y, Sawakuchi GO, Beddar S, Katz MH, Fleming JB, Javle MM, Varadhachary GR, Wolff RA, Crane CH, Wang X, Thames H, Krishnan S. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?. Int J Radiat Oncol Biol Phys 97(2):323-332, 2017. e-Pub 2017. PMID: 28068240.
155. Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg 21(1):164-174, 2017. e-Pub 2017. PMID: 27778257.
156. Denbo JW, Bruno ML, Cloyd JM, Prakash L, Lee JE, Kim M, Crane CH, Koay EJ, Krishnan S, Das P, Minsky BD, Varadhachary G, Shroff R, Wolff R, Javle M, Overman MJ, Fogelman D, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg 20(12):1975-1985, 2016. e-Pub 2016. PMID: 27730398.
157. Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, Wu C, Shroff RT, Chen JL, Bekaii-Saab T. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer 122(23):3657-3666, 2016. e-Pub 2016. PMID: 27495988.
158. Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J. Biliary Cancer: Utility of Next Generation Sequencing for Clinical Management. Cancer 122(24):3838-3847, 2016. e-Pub 2016. PMID: 27622582.
159. Yamashita S, Loyer E, Chun YS, Javle M, Lee JE, Vauthey JN, Conrad C. Laparoscopic Management of Gallbladder Cancer: A Stepwise Approach. Ann Surg Oncol 23(Suppl 5):892-893, 2016. e-Pub 2016. PMID: 27456958.
160. Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol 7(6):819-827, 2016. e-Pub 2016. PMID: 28078106.
161. Chadha AS, Gunther JR, Minsky BD, Taniguchi CM, Mahmood U, Delclos ME, Suh Y, Sawakuchi GO, Park PC, Beddar S, Gupta S, Kaur H, Javle MM, Kaseb AO, Koay EJ, Das P, Crane CH, Krishnan S. Proton Therapy Outcomes for Localized, Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 96(2S):E181-E182, 2016. e-Pub 2016. PMID: 27673993.
162. Amer AM, Tao R, Kang H, Chun Y, Vauthey JN, Javle MM, Kaseb AO, Crane CH, Koay EJ. Quantitative European Association for the Study of the Liver (qEASL) as an Early Biomarker of Response After Radiation Therapy for Intrahepatic Cholangiocarcinoma. Int J Radiat Oncol Biol Phys 96(2S):S202, 2016. e-Pub 2016. PMID: 27675783.
163. Al-Shamsi HO, Anand D, Shroff RT, Jain A, Zuo M, Conrad C, Vauthey JN, Javle MM. BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype. J Gastrointest Oncol 7(4):556-61, 2016. e-Pub 2016. PMID: 27563445.
164. Ismael HN, Denbo J, Cox S, Crane CH, Das P, Krishnan S, Schroff RT, Javle M, Conrad C, Vauthey J, Aloia T. Biologic mesh spacer placement facilitates safe delivery of dose-intense radiation therapy: A novel treatment option for unresectable liver tumors. Eur J Surg Oncol. e-Pub 2016. PMID: 27296729.
165. Lee H, Wang K, Johnson A, Jones DM, Ali SM, Elvin JA, Yelensky R, Lipson D, Miller VA, Stephens PJ, Javle M, Ross JS. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. J Clin Pathol 69(5):403-8, 2016. e-Pub 2016. PMID: 26500333.
166. Cloyd JM, Crane CH, Koay EJ, Das P, Krishnan S, Prakash L, Snyder RA, Varadhachary GR, Wolff RA, Javle M, Shroff RT, Fogelman D, Overman M, Wang H, Maitra A, Lee JE, Fleming JB, Katz MH. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. e-Pub 2016. PMID: 27243381.
167. Zuo M, Rashid A, Wang Y, Jain A, Li D, Behari A, Kumar Kapoor V, Koay EJ, Chang P, Nicholas Vauthey J, Li Y, Espinoza JA, Carlos Roa J, Javle M. RNA sequencing-based analysis of gallbladder cancer reveals the importance of the liver X receptor and lipid metabolism in gallbladder cancer. Oncotarget. e-Pub 2016. PMID: 27167107.
168. Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB, Urba S, Yee NS. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. e-Pub 2016. PMID: 27247216.
169. Tjensvoll K, Lapin M, Buhl T, Oltedal S, Steen-Ottosen Berry K, Gilje B, Søreide JA, Javle M, Nordgård O, Smaaland R. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Mol Oncol 10(4):635-43, 2016. e-Pub 2016. PMID: 26725968.
170. Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das P, Minsky BD, Mahmood U, Delclos ME, Sawakuchi GO, Beddar S, Katz MH, Fleming JB, Javle MM, Varadhachary GR, Wolff RA, Crane CH. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int J Radiat Oncol Biol Phys 94(4):755-65, 2016. e-Pub 2016. PMID: 26972648.
171. Roa I, Garcia H, Game A, de Toro G, de Aretxabala X, Javle M. Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer: Further Options for an Orphan Cancer. J Mol Diagn. e-Pub 2016. PMID: 26947513.
172. Chen J, Yao ZX, Chen JS, Gi YJ, Muñoz NM, Kundra S, Herlong HF, Jeong YS, Goltsov A, Ohshiro K, Mistry NA, Zhang J, Su X, Choufani S, Mitra A, Li S, Mishra B, White J, Rashid A, Wang AY, Javle M, Davila M, Michaely P, Weksberg R, Hofstetter WL, Finegold MJ, Shay JW, Machida K, Tsukamoto H, Mishra L. TGF-β/β2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome. J Clin Invest 126(2):527-42, 2016. e-Pub 2016. PMID: 26784546.
173. Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 34(5):460-8, 2016. e-Pub 2016. PMID: 26668346.
174. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, Kaseb AO, Bishop AJ, Swanick CW, Koay EJ, Thames HD, Hong TS, Das P, Crane CH. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol 34(3):219-26, 2016. e-Pub 2016. PMID: 26503201.
175. Chadha AS, Skinner HD, Gunther JR, Munsell MF, Das P, Minsky BD, Delclos ME, Chatterjee D, Wang H, Clemons M, George G, Singh PK, Katz MH, Fleming JB, Javle MM, Wolff RA, Varadhachary GR, Crane CH, Krishnan S. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS One 11(6):e0156910, 2016. e-Pub 2016. PMID: 27336466.
176. Chen J, Raju GS, Jogunoori W, Menon V, Majumdar A, Chen JS, Gi YJ, Jeong YS, Phan L, Belkin M, Gu S, Kundra S, Mistry NA, Zhang J, Su X, Li S, Lin SH, Javle M, McMurray JS, Rahlfs TF, Mishra B, White J, Rashid A, Beauchemin N, Weston BR, Shafi MA, Stroehlein JR, Davila M, Akbani R, Weinstein JN, Wu X, Mishra L. Mutational Profiles Reveal an Aberrant TGF-β-CEA Regulated Pathway in Colon Adenomas. PLoS One 11(4):e0153933, 2016. e-Pub 2016. PMID: 27100181.
177. Roland CL, Katz MH, Tzeng CW, Lin H, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Vauthey JN, Crane CH, Lee JE, Fleming JB. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol 22 Suppl 3:1221-8, 2015. e-Pub 2015. PMID: 26350371.
178. Fogelman D, Sugar EA, Oliver G, Shah N, Klein A, Alewine C, Wang H, Javle M, Shroff R, Wolff RA, Abbruzzese JL, Laheru D, Diaz LA. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol 76(3):489-98, 2015. e-Pub 2015. PMID: 26126726.
179. Aloia TA, Járufe N, Javle M, Maithel SK, Roa JC, Adsay V, Coimbra FJ, Jarnagin WR. Gallbladder Cancer: expert consensus statement. HPB (Oxford) 17(8):681-90, 2015. e-Pub 2015. PMID: 26172135.
180. Chadha AS, Kocak-Uzel E, Das P, Minsky BD, Delclos ME, Mahmood U, Guha S, Ahmad M, Varadhachary GR, Javle M, Katz MH, Fleming JB, Wolff RA, Crane CH, Krishnan S. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol 54(7):971-8, 2015. e-Pub 2015. PMID: 25608822.
181. Zuo M, Li C, Lin J, Javle M. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy. Oncotarget 6(13):10940-9, 2015. e-Pub 2015. PMID: 25883212.
182. Shindoh J, de Aretxabala X, Aloia TA, Roa JC, Roa I, Zimmitti G, Javle M, Conrad C, Maru DM, Aoki T, Vigano L, Ribero D, Kokudo N, Capussotti L, Vauthey JN. Tumor Location Is a Strong Predictor of Tumor Progression and Survival in T2 Gallbladder Cancer: An International Multicenter Study. Ann Surg 261(4):733-9, 2015. e-Pub 2015. PMID: 24854451.
183. Zuo M, Rashid A, Churi C, Vauthey JN, Chang P, Li Y, Hung MC, Li D, Javle M. Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer. Br J Cancer 112(6):1042-51, 2015. e-Pub 2015. PMID: 25742482.
184. Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, Mishra L, Wolff RA, Kaseb AO, Thomas MB, Siegel AB. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol 8:58, 2015. e-Pub 2015. PMID: 26022204.
185. Roa I, de Toro G, Fernández F, Game A, Muñoz S, de Aretxabala X, Javle M. Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer. Diagn Pathol 10:148, 2015. e-Pub 2015. PMID: 26294099.
186. Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, Shroff RT. Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol 5(6):408-413, 2014. e-Pub 2014. PMID: 25436118.
187. Javle M, Smyth EC, Chau I. Ramucirumab: Successfully Targeting Angiogenesis in Gastric Cancer. Clin Cancer Res 20(23):5875-81, 2014. e-Pub 2014. PMID: 25281695.
188. Anwar S, Tan W, Yu J, Hutson A, Javle M, Iyer R. Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial. J Gastrointest Oncol 5(6):433-439, 2014. e-Pub 2014. PMID: 25436122.
189. Fogelman DR, Holmes H, Mohammed K, Katz MH, Prado CM, Lieffers J, Garg N, Varadhachary GR, Shroff R, Overman MJ, Garrett C, Wolff RA, Javle M. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?. J Cachexia Sarcopenia Muscle 5(4):307-313, 2014. e-Pub 2014. PMID: 24740741.
190. Huguet F, Mukherjee S, Javle M. Locally advanced pancreatic cancer: the role of definitive chemoradiotherapy. Clin Oncol (R Coll Radiol) 26(9):560-8, 2014. e-Pub 2014. PMID: 25001636.
191. Liu C, Karam R, Zhou Y, Su F, Ji Y, Li G, Xu G, Lu L, Wang C, Song M, Zhu J, Wang Y, Zhao Y, Foo WC, Zuo M, Valasek MA, Javle M, Wilkinson MF, Lu Y. The UPF1 RNA Surveillance Gene is Commonly Mutated in Pancreatic Adenosquamous Carcinoma. Nat Med 20(6):596-8, 2014. e-Pub 2014. PMID: 24859531.
192. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43(3):343-9, 2014. e-Pub 2014. PMID: 24622062.
193. Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Varadhachary GR, Ferrari M, Fleming JB. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest 124(4):1525-36, 2014. e-Pub 2014. PMID: 24614108.
194. Javle M, Rashid A, Churi C, Kar S, Zuo M, Eterovic AK, Nogueras-Gonzalez GM, Janku F, Shroff RT, Aloia TA, Vauthey JN, Curley S, Mills G, Roa I. Molecular Characterization of Gallbladder Cancer using Somatic Mutation Profiling. Hum Pathol 45(4):701-8, 2014. e-Pub 2014. PMID: 24508317.
195. Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, Javle M. Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer?. Gastrointest Cancer Res 7(2):42-8, 2014. e-Pub 2014. PMID: 24799970.
196. Tanasanvimon S, Garg N, Viswanathan C, Truong M, Kaur H, Kee BK, Sahin IH, Javle MM, Garrett CR. High prevalence of recurrent thrombosis in subsets of cancer patients with isolated gonadal vein thrombosis: a single center retrospective study. Thromb Res 133(2):154-7, 2014. e-Pub 2014. PMID: 24331209.
197. Koay EJ, Baio FE, Ondari A, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Zhang J, Court L, Bhosale PR, Tamm EP, Qayyum A, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Maitra A, Ferrari M, Varadhachary GR, Fleming JB. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol 11(6):065002, 2014. e-Pub 2014. PMID: 25427073.
198. Javle M, Li Y, Tan D, Dong X, Chang P, Kar S, Li D. Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer. PLoS One 9(1):e85942, 2014. e-Pub 2014. PMID: 24465802.
199. Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, Janku F, Crane CH, Mishra L, Vauthey JN, Wolff RA, Mills G, Javle M. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 9(12):e115383, 2014. e-Pub 2014. PMID: 25536104.
200. Das P, Abboud MT, Haque W, Javle M, Kaseb A, Curley SA, Vauthey JN, Aloia TA, Beddar AS, Delclos ME, Krishnan S, Crane CH. Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. Pract Radiat Oncol 3(4):344-8, 2013. e-Pub 2013. PMID: 24674408.
201. Kunkeaw N, Jeon SH, Lee K, Johnson BH, Tanasanvimon S, Javle M, Pairojkul C, Chamgramol Y, Wongfieng W, Gong B, Leelayuwat C, Lee YS. Cell death/proliferation roles for nc886, a non-coding RNA, in the protein kinase R pathway in cholangiocarcinoma. Oncogene 32(32):3722-31, 2013. e-Pub 2013. PMID: 22926522.
202. Khalil MA, Qiao W, Carlson P, George B, Javle M, Overman M, Varadhachary G, Wolff RA, Abbruzzese JL, Fogelman DR. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. e-Pub 2013. PMID: 23645398.
203. Atiq M, Bhutani MS, Ross WA, Raju GS, Gong Y, Tamm EP, Javle M, Wang X, Lee JH. Role of endoscopic ultrasonography in evaluation of metastatic lesions to the pancreas: a tertiary cancer center experience. Pancreas 42(3):516-23, 2013. e-Pub 2013. PMID: 23211369.
204. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 4(1):156-65, 2013. e-Pub 2013. PMID: 23391555.
205. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials. Oncotarget 4(1):153-62, 2013. e-Pub 2013. PMID: 23847722.
206. Hecht JR, Farrell JJ, Senzer N, Nemunaitis J, Rosemurgy A, Chung T, Hanna N, Chang KJ, Javle M, Posner M, Waxman I, Reid A, Erickson R, Canto M, Chak A, Blatner G, Kovacevic M, Thornton M. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc 75(2):332-8, 2012. e-Pub 2012. PMID: 22248601.
207. Katz MH, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E, Evans DB, Lee JE, Fleming JB, Pisters PW. Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial. Ann Surg Oncol 18(13):3615-22, 2011. e-Pub 2011. PMID: 21701927.
208. Singal AK, Ross WA, Guturu P, Varadhachary GR, Javle M, Jaganmohan SR, Raju RP, Fleming JB, Raju GS, Kuo YF, Lee JH. Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer: single-center experience with 79 cases. Dig Dis Sci 56(12):3678-84, 2011. e-Pub 2011. PMID: 21750930.
209. Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol 3(6):257-67, 2011. e-Pub 2011. PMID: 22084640.
210. Skinner HD, Sharp HJ, Kaseb AO, Javle MM, Vauthey JN, Abdalla EK, Delclos ME, Das P, Crane CH, Krishnan S. Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol 50(8):1191-8, 2011. e-Pub 2011. PMID: 21793641.
211. Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 105(8):1114-22, 2011. e-Pub 2011. PMID: 21989215.
212. Eckmann KR, Patel DK, Landgraf A, Slade JH, Lin E, Kaur H, Loyer E, Weatherly JM, Javle M. Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. Gastrointest Cancer Res 4(5-6):155-60, 2011. e-Pub 2011. PMID: 22295126.
213. El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs 29(4):694-9, 2011. e-Pub 2011. PMID: 20107864.
214. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29(22):3037-43, 2011. e-Pub 2011. PMID: 21709185.
215. Raju RP, Jaganmohan SR, Ross WA, Davila ML, Javle M, Raju GS, Lee JH. Optimum Palliation of Inoperable Hilar Cholangiocarcinoma: Comparative Assessment of the Efficacy of Plastic and Self-Expanding Metal Stents. Dig Dis Sci 56(5):1557-64, 2011. e-Pub 2011. PMID: 21222156.
216. Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res 31(4):1417-20, 2011. e-Pub 2011. PMID: 21508395.
217. Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. National Institute of Health 116(22):5325-35, 2010. e-Pub 2010. PMID: 20665488.
218. Atiq M, Javle M, Dang S, Lee JH. Cholangiocarcinoma: an endoscopist's perspective. Expert Rev Gastroenterol Hepatol 4(5):601-11, 2010. e-Pub 2010. PMID: 20932145.
219. Huang TC, Kar S, Javle M. Personalized therapy for pancreatic cancer: Myth or reality in 2010?. J Gastrointest Oncol 1(1):24-33, 2010. e-Pub 2010. PMID: 22811802.
220. Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL, Li D. Insulin-like Growth Factor Axis Gene Polymorphisms and Clinical Outcomes in Pancreatic Cancer. National Institute of Health - Gastroenterology 139(2):464-73, 473.e1-3, 2010. e-Pub 2010. PMID: 20416304.
221. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116(8):1938-46, 2010. e-Pub 2010. PMID: 20166205.
222. May KS, Khushalani NI, Chandrasekhar R, Wilding GE, Iyer RV, Ma WW, Flaherty L, Russo RC, Fakih M, Kuvshinoff BW, Gibbs JF, Javle MM, Yang GY. Analysis of Clinical and Dosimetric Factors Associated with Change in Renal Function in Patients with Gastrointestinal Malignancies After Chemoradiation to the Abdomen. Int J Radiat Oncol Biol Phys 76(4):1193-8, 2010. e-Pub 2010. PMID: 19540051.
223. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 16(1):320-9, 2010. e-Pub 2010. PMID: 20028759.
224. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 10:368, 2010. e-Pub 2010. PMID: 20630061.
225. Lo SS, Khorana AA, Javle M, Simon S, Kiefer G, Rajasenan K, Wang H, Hantel A, Shayne M, Hwang J, Schmotzer A, Ramanathan RK. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. Oncology 78(2):125-9, 2010. e-Pub 2010. PMID: 20389134.
226. Chadha MK, Lombardo J, Mashtare T, Wilding GE, Litwin A, Raczyk C, Gibbs JF, Kuvshinoff B, Javle MM, Iyer RV. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res 10(10):4127-30, 2009. e-Pub 2009. PMID: 19846960.
227. Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A, Phelan J, Gibbs J, Iyer R. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. British Journal of Cancer 100(12):1842-5, 2009. e-Pub 2009. PMID: 19491904.
228. Brell JM, Krishnamurthi SS, Javle M, Saltzman J, Wollner I, Pelley R, Dowlati A, Kantharaj BN, Schluchter MD, Rath L, Ivy SP, Remick SC. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemother Pharmacol 63(5):851-7, 2009. e-Pub 2009. PMID: 18670776.
229. Javle MM, Yang G, Nwogu CE, Wilding GE, O'Malley L, Vinjamaram S, Schiff MD, Nava HR, LeVea C, Clark KR, Prey JD, Smith PF, Pendyala L. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Invest 27(2):193-200, 2009. e-Pub 2009. PMID: 19235592.
230. Javle M, Hsueh CT. Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 2:9, 2009. e-Pub 2009. PMID: 19236713.
231. Haque W, Crane CH, Krishnan S, Delclos ME, Javle M, Garrett CR, Wolff RA, Das P. Reirradiation to the abdomen for gastrointestinal malignancies. Radiat Oncol 4:55, 2009. e-Pub 2009. PMID: 19922641.
232. Chadha MK, Litwin A, Levea C, Iyer R, Yang G, Javle M, Gibbs JF. Surgical resection after TNFerade therapy for locally advanced pancreatic cancer. JOP 10(5):535-8, 2009. e-Pub 2009. PMID: 19734632.
233. Javle M, Pande A, Iyer R, Yang G, LeVea C, Wilding G, Black J, Nava H, Nwogu C. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am J Clin Oncol 31(4):329-34, 2008. e-Pub 2008. PMID: 18845990.
234. Javle MM, Gibbs JF, Iwata KK, Pak Y, Rutledge P, Yu J, Black JD, Tan D, Khoury T. Epithelial-Mesenchymal Transition (EMT) and Activated Extracellular Signal-regulated Kinase (p-Erk) in Surgically Resected Pancreatic Cancer. Ann Surg Oncol 14(12):3527-33, 2007. e-Pub 2007. PMID: 17879119.
235. Iyer RV, Gibbs J, Kuvshinoff B, Fakih M, Kepner J, Soehnlein N, Lawrence D, Javle MM. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol 14(11):3202-9, 2007. e-Pub 2007. PMID: 17705089.
236. Pande A, Lombardo J, Spangenthal E, Javle M. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res 27(5B):3465-70, 2007. e-Pub 2007. PMID: 17972502.
237. Patt YZ, Lee FC, Liebmann JE, Diamandidis D, Eckhardt SG, Javle M, Justice GR, Keiser W, Salvatore JR, Bexon A, Lin E. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol 30(4):350-7, 2007. e-Pub 2007. PMID: 17762434.
238. Ailawadhi S, Nagase H, Khoury T, Yu J, Tan D, Black J, Brattain M, Javle M. Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma. Hepatogastroenterology 54(77):1339-44, 2007. e-Pub 2007. PMID: 17708250.
239. Javle M, Yang GY. Review: neoadjuvant chemoradiotherapy and chemotherapy improve survival in operable esophageal cancer. ACP J Club 147(1):19, 2007. e-Pub 2007. PMID: 17608384.
240. Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol 59(5):581-7, 2007. e-Pub 2007. PMID: 17066293.
241. Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada-Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O'bryant CL, Creaven PJ. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res 133(7):2091-9, 2007. e-Pub 2007. PMID: 17404091.
242. Agrawal S, Kuvshinoff BW, Khoury T, Yu J, Javle MM, LeVea C, Groth J, Coignet LJ, Gibbs JF. CD24 Expression is an Independent Prognostic Marker in Cholangiocarcinoma. J Gastrointest Surg 11(4):445-51, 2007. e-Pub 2007. PMID: 17436128.
243. Javle M, Shah P, Yu J, Bhagat V, Litwin A, Iyer R, Gibbs J. Cystic pancreatic tumors (CPT): Predictors of malignant behavior. J Surg Oncol 95(3):221-228, 2007. e-Pub 2007. PMID: 17323335.
244. Foster J, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF. COX-2 expression in hepatocellular carcinoma is an initiation event, while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. Ann Surg Oncol 14(2):752-8, 2007. e-Pub 2007. PMID: 17146741.
245. Foster JM, Hoshi H, Gibbs JF, Iyer R, Javle M, Chu Q, Kuvshinoff B. Gallbladder cancer: Defining the indications for primary radical resection and radical re-resection. Ann Surg Oncol 14(2):833-40, 2007. e-Pub 2007. PMID: 17103074.
246. Javle MM, Cao S, Durrani FA, Pendyala L, Lawrence DD, Smith PF, Creaven PJ, Noel DC, Iyer RV, Rustum YM. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Clin Cancer Res 13(3):965-71, 2007. e-Pub 2007. PMID: 17289892.
247. OConnor BM, Chadha MK, Pande A, Lombardo JC, Nwogu CE, Nava HR, Yang G, Javle MM. Concurrent oxaliplatin, 5-fluouracil and radiation for esophageal cancer. Cancer Journal 13(2):119, 2007. e-Pub 2007.
248. Donthireddy KR, Schiff MD, Ailawadhi S, Javle M. Malignant Gastroparesis: An under-recognized entity. J of Supportive Oncology 5(8):355, 2007. e-Pub 2007.
249. Chadha KS, Hernandez-Ilizaliturri FJ, Javle M. Primary esophageal lymphoma: case series and review of the literature. Dig Dis Sci 51(1):77-83, 2006. e-Pub 2006. PMID: 16416216.
250. Jayaprakash V, Menezes RJ, Javle MM, McCann SE, Baker JA, Reid ME, Natarajan N, Moysich KB. Regular aspirin use and esophageal cancer risk. Int J Cancer 119(1):202-207, 2006. e-Pub 2006. PMID: 16450404.
251. Javle M, Ailawadhi S, Yang GY, Nwogu CE, Schiff MD, Nava HR. Palliation of malignant dysphagia in esophageal cancer: a literature-based review. J Support Oncol 4(8):365-73, 379, 2006. e-Pub 2006.
252. Javle M, Yu J, Khoury T, Chadha KC, Iyer RV, Foster J, Kuvshinoff BW, Gibbs JF, Geradts J, Black JD, Brattain MG. Akt expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol 21(11):1744-51, 2006. e-Pub 2006.
253. Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, Tan D, Brattain MG, Javle MM. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 13(7):933-9, 2006. e-Pub 2006. PMID: 16715446.
254. Javle M, Nwogu CE, Donohue KA, Iyer RV, Brady WE, Khemka SV, Smith JL, Demmy TL, Yang GY, Nava HR. Management of locoregional stage esophageal cancer: A single center experience. Dis. Of Esophagus 19(2):78-83, 2006. e-Pub 2006.
255. Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 4(4):350-366, 2006. e-Pub 2006. PMID: 16569388.
256. Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Esophageal Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 4(4):328-347, 2006. e-Pub 2006. PMID: 16569387.
257. Leichman L, Lawrence D, Leichmen C, Hava H, Nava E, Proulx G, Clark K, Khushalani N, Berdzik J, Greco W, Smith P, Creaven P, Kepner J, Javle M, Pendyala L. Expression of genes related to the activity of oxaliplatin, 5-fluorouracil and radiation: characterization and exploratory analysis with survival. J Chemother 18(5):514-24, 2006. e-Pub 2006.
258. Chadha KS, Hernandez-Illizaliturri FJ, Javle M. Primary esophageal lymphoma: Case series and review of the literature. Dig Dis Sci 51:77-83, 2006. e-Pub 2006.
259. Watwe V, Javle M, Lawrence D, Groth J, Iyer R, El-Hajjar D, Geradts J. Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer. Am J Clin Oncol 28(6):560-4, 2005. e-Pub 2005. PMID: 16317264.
260. Ramnath N, Khushalani, N, Toth K, Litwin A, Intengen M, Slocum HK, Pendyala L, Smith P, Stewart C, Hoffman J, Javle M, Berdzik J, Creaven PJ, Rustum YM. S-Phase Modulation by Irinotecan: Pilot Studies in Advanced Solid Tumors. Cancer Chemotherapy and Pharmacology 56(5):447-454, 2005. e-Pub 2005.
261. Fakih MG, Creaven PJ, Ramnath N, Trump D, Javle M, Strychor S, Repinski TV, Zamboni BA, Schwarz JK, French RA, Zamboni WC. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors. Clin Cancer Res 11(16):5942-9, 2005. e-Pub 2005. PMID: 16115937.
262. Bahadur S, Shaukat A, Gibbs J, Litwin A, Nava H, Melnyk M, Javle M. Cisplatin and Gemcitabine for small cell carcinoma of the gall bladder. Am J Clin Oncol 28(4):425-426, 2005. e-Pub 2005. PMID: 16062088.
263. Javle M. Salvage Esophagectomy for Recurrent Esophageal Adenocarcinoma: A Viable Option for Chemotherapy Responders. Hem Onc. Today, 2005. e-Pub 2005.
264. Mortazavi A, Shaukat A, Othman E, Kepner JL, Fakih MG, Kuvshinoff BW, Smith JL, Javle MM. Postoperative computed tomography scan surveillance for patients with stage II and III colorectal cancer: worthy of further study?. Am J Clin Oncol 28(1):30-35, 2005. e-Pub 2005. PMID: 15685032.
265. Nallapareddy S, Wilding GE, Yang G, Iyer R, Javle M. Chemoradiation is a Tolerable Therapy for Older Adults with Esophageal Cancer. Anticancer Res 25(4):3055-3060, 2005. e-Pub 2005. PMID: 16080565.
266. Tripp P, Malhotra HK, Javle M, Shaukat A, Russo R, De Boer S, Podgorsak M, Nava H, Yang GY. Cardiac function after chemoradiation for esophageal cancer: comparison of heart dose-volume histogram parameters to multiple gated acquisition scan changes. Dis Esophagus 18(6):400-405, 2005. e-Pub 2005. PMID: 16336612.
267. Beer TM, Javle M, Lam GN, Henner WD, Wong A, Trump DL. Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer. Clin Cancer Res 11(21):7794-7799, 2005. e-Pub 2005. PMID: 16278401.
268. Khoury T, Chadha K, Javle M, Donohue K, Levea C, Iyer R, Okada H, Nagase H, Tan D. Expression of Intestinal Trefoil Factor (TFF-3) in hepatocellular carcinoma. Int J Gastrointest Cancer 35(3):171-177, 2005. e-Pub 2005. PMID: 16110118.
269. Watwe V, Farrell CD, Javle M. Muir-Torre Syndrome associated with Turcot syndrome. Internet Journal of Gastroenterology 3(2):online, 2005. e-Pub 2005.
270. James TA, Sheldon DG, Rajput A, Kuvshinoff BW, Javle MM, Nava HR, Smith JL, Gibbs JF. Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer 101(12):2722-2726, 2004. e-Pub 2004. PMID: 15534880.
271. Gowda A, Goel R, Berdzik J, Leichman CG, Javle M. Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology (Williston Park) 18(13):1671-5; discussion 1676, 1680, 1683-4, 2004. e-Pub 2004. PMID: 15648298.
272. Javle MM, Tan D, Yu J, LeVea CM, Li F, Kuvshinoff BW, Gibbs JF. Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology 51(60):1653-1657, 2004. e-Pub 2004. PMID: 15532797.
273. Wilkinson NW, Black JD, Roukhadze E, Driscoll D, Smiley S, Hoshi H, Geradts J, Javle M, Brattain M. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 8(4):448-53, 2004. e-Pub 2004. PMID: 15120370.
274. Iyer R, Wilkinson N, Demmy T, Javle M. Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined-modality therapy. Ann Surg Oncol 11:665-673, 2004. e-Pub 2004.
275. Palesty JA, Wang W, Javle MM, Yang GY. Side effects of therapy: case 3. Gastric cancer after radiotherapy of pediatric Hodgkin's disease. J Clin Oncol 22(12):2507-2509, 2004. e-Pub 2004. PMID: 15197215.
276. Shaukat A, Mortazavi A, Demmy T, Nava H, Wilkinson N, Yang G, Kepner J, Javle M. Should preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients?. Dis Esophagus 17:129-135, 2004. e-Pub 2004.
277. Bhagat V, Javle M, Geradts J. Carcinoma of the esophagus with mixed basaloid squamous and glandular differentiation: a distinct histological presentation. Int J Gastrointest Cancer 34(2-3):139-142, 2003. e-Pub 2003. PMID: 15361648.
278. Chu QD, Khushalani N, Javle MM, Jr DH, Gibbs JF. Should adjuvant therapy remain the standard of care for patients with resected adenocarcinoma of the pancreas?. Ann Surg Oncol 10:539-545, 2003. e-Pub 2003.
279. Varma GN, Winston JS, Hill HC, Gibbs JF, Proulx GM, McGrath BE, Javle MM. Unusual locations of involvement by malignancies: Case 3. Gastric signet ring carcinoma presenting as a diffuse thigh mass. J Clin Oncol 21(17):3371-3373, 2003. e-Pub 2003. PMID: 12947076.
280. Creaven PJ, Slocum HK, Toth K, Pendyala L, Smith P, Litwin A, Intengan M, Javle MM, Ramnath N, Loewen G, Rustum YM. Modulation of 5-Fluorouracil by Irinotecan in advanced solid tumors-A pilot study. Intl J Cancer suppl 13:94, 2002. e-Pub 2002.
281. Creaven P, Javle M, Raghavan D. Taxol based chemotherapy for non-small cell lung cancer. Advances in Oncology 15:18-24, 1999. e-Pub 1999.
282. Javle M, Raghavan D. Systemic Therapy for Invasive Bladder Cancer. Cancer Control 3(6):501-506, 1996. e-Pub 1996. PMID: 10764508.

Invited Articles

1. Javle M. Gastroparesis from Advanced Cancer. Uptodate online, 2008. e-Pub 2008.

Review Articles

1. Adesoye, T, Ileana Dumbrava, EE, Raghav, KS, Sahin, AA, Chen, H, Lee, SS, Javle, M, Pant, S, Alhalabi, O, Le, X, Valero, V, Pohlmann, PR, Meric-Bernstam, F. Advances in Targeting HER2 across Cancer Subtypes. Clinical Cancer Research 32(2):260-290, 2026. e-Pub 2026. PMID: 41283902.
2. Varshney, P, Baghmar, S, Sirohi, B, Abou-Alfa, GK, Cao, HT, Sharma, LM, Javle, M, Goetze, TO, Kapoor, VK. Neoadjuvant treatment for incidental gallbladder cancer. Annals of Hepato-Biliary-Pancreatic Surgery 29(2):113-120, 2025. e-Pub 2025. PMID: 40064481.
3. Javle M, King G, Spencer K, Borad MJ. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors. Oncologist 28(11):928-943, 2023. e-Pub 2023. PMID: 37390492.
4. Koay EJ, Javle M, Belknap M, Derasari S, Roach M, Ludmir EB. What Role Does Radiotherapy Play in the Molecular Era for Intrahepatic Cholangiocarcinoma?. Cancer J 29(5):272-278, 2023. e-Pub 2023. PMID: 37796645.
5. Abboud K, Umoru G, Esmail A, Abudayyeh A, Murakami N, Al-Shamsi HO, Javle M, Saharia A, Connor AA, Kodali S, Ghobrial RM, Abdelrahim M. Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology. Cancers (Basel) 15(5), 2023. e-Pub 2023. PMID: 36900226.
6. Connor AA, Kodali S, Abdelrahim M, Javle MM, Brombosz EW, Ghobrial RM. Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkers. Front Oncol 12:996710, 2022. e-Pub 2022. PMID: 36479082.
7. Gupta P, Dutta U, Rana P, Singhal M, Gulati A, Kalra N, Soundararajan R, Kalage D, Chhabra M, Sharma V, Gupta V, Yadav TD, Kaman L, Irrinki S, Singh H, Sakaray Y, Das CK, Saikia U, Nada R, Srinivasan R, Sandhu MS, Sharma R, Shetty N, Eapen A, Kaur H, Kambadakone A, de Haas R, Kapoor VK, Barreto SG, Sharma AK, Patel A, Garg P, Pal SK, Goel M, Patkar S, Behari A, Agarwal AK, Sirohi B, Javle M, Garcea G, Nervi F, Adsay V, Roa JC, Han HS. Gallbladder reporting and data system (GB-RADS) for risk stratification of gallbladder wall thickening on ultrasonography: an international expert consensus. Abdom Radiol (NY) 47(2):554-565, 2022. e-Pub 2022. PMID: 34851429.
8. King G, Javle M. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. Curr Oncol Rep 23(9):108, 2021. e-Pub 2021. PMID: 34269915.
9. Kommalapati A, Tella SH, Borad M, Javle M, Mahipal A. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. Cancers (Basel) 13(12), 2021. e-Pub 2021. PMID: 34199304.
10. Sapisochin G, Javle M, Lerut J, Ohtsuka M, Ghobrial M, Hibi T, Kwan NM, Heimbach J. Liver Transplantation for Cholangiocarcinoma and Mixed Hepatocellular Cholangiocarcinoma: Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 104(6):1125-1130, 2020. e-Pub 2020. PMID: 32217937.
11. Athauda A, Fong C, Lau DK, Javle M, Abou-Alfa GK, Morizane C, Steward K, Chau I. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treat Rev 86:101998, 2020. e-Pub 2020. PMID: 32203843.
12. Mosconi C, Calandri M, Javle M, Odisio BC. Interventional radiology approaches for intra-hepatic cholangiocarcinoma. Chin Clin Oncol 9(1):8, 2020. e-Pub 2020. PMID: 32008330.
13. Mehrotra R, Tulsyan S, Hussain S, Mittal B, Singh Saluja S, Singh S, Tanwar P, Khan A, Javle M, Hassan MM, Pant S, De Aretxabala X, Sirohi B, Rajaraman P, Kaur T, Rath GK. Genetic landscape of gallbladder cancer: Global overview. Mutat Res 778:61-71, 2018. e-Pub 2018. PMID: 30454684.
14. Golan T, Javle M. DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development. J Natl Compr Canc Netw 15(8):1063-1069, 2017. e-Pub 2017. PMID: 28784866.
15. Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist 22(7):804-810, 2017. e-Pub 2017. PMID: 28487467.
16. Koay EJ, Odisio BC, Javle M, Vauthey JN, Crane CH. Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?. Hepatobiliary Surg Nutr 6(2):105-116, 2017. e-Pub 2017. PMID: 28503558.
17. Jain A, Kwong LN, Javle M. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Curr Treat Options Oncol 17(11):58, 2016. e-Pub 2016. PMID: 27658789.
18. Jain A, Javle M. Molecular profiling of biliary tract cancer: a target rich disease. J Gastrointest Oncol 7(5):797-803, 2016. e-Pub 2016. PMID: 27747093.
19. Espinoza JA, Bizama C, García P, Ferreccio C, Javle M, Miquel JF, Koshiol J, Roa JC. The inflammatory inception of gallbladder cancer. Biochim Biophys Acta 1865(2):245-54, 2016. e-Pub 2016. PMID: 26980625.
20. Javle M, Golan T, Maitra A. Changing the course of pancreatic cancer - Focus on recent translational advances. Cancer Treat Rev 44:17-25, 2016. e-Pub 2016. PMID: 26924195.
21. Golan T, Javle M. Targeting the insulin growth factor pathway in gastrointestinal cancers. Oncology (Williston Park) 25(6):518-26, 529, 2011. e-Pub 2011. PMID: 21717907.
22. Javle M, Hsueh CT. Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 3:11, 2010. e-Pub 2010. PMID: 20331897.
23. Pan JJ, Javle M, Thinn MM, Hsueh CT, Hsueh CT. Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. Hepat Med 2:147-55, 2010. e-Pub 2010. PMID: 24367212.
24. Ettinger DS, Agulnik M, Cristea M, Eaton K, Fidias PM, Gockerman JP, Hameed O, Handorf C, Harris EI, Jacobs CD, Javle M, Khushalani NI, Kvols L, Lenzi R, Lewis NL, Rashid A, Saltz L, Shulman LN, Zager JS, Zhen W. Occult primary. J Natl Compr Canc Netw 6(10):1026-60, 2008. e-Pub 2008. PMID: 19176200.
25. Donthireddy KR, Ailawadhi S, Nasser E, Schiff MD, Nwogu CE, Nava HR, Javle MM. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol 5(8):355-63, 2007. e-Pub 2007. PMID: 17944143.
26. Pande AU, Iyer RV, Rani A, Maddipatla S, Yang GY, Nwogu CE, Black JD, Levea CM, Javle MM. Epidermal growth factor receptor-directed therapy in esophageal cancer. Oncology 73(5-6):281-9, 2007. e-Pub 2007. PMID: 18477853.
27. Bdair FM, Graham SP, Smith PF, Javle MM. Gemcitabine and acute myocardial infarction--a case report. Angiology 57(3):367-71, 2006. e-Pub 2006. PMID: 16703198.
28. Bhagat V, Javle M, Yu J, Agrawal A, Gibbs JF, Kuvshinoff B, Nava E, Iyer R. Combined Hepatocholangiocarcinoma: case-series and review of literature. Int J Gastrointest Cancer 37(1):27-34, 2006. e-Pub 2006. PMID: 17290078.
29. Ailawadhi S, Shenoy S, Sham R, Javle M. Transarterial chemoembolization in a patient with recurrent hepatocellular carcinoma and portal vein thrombosis: a case report and review of the literature. Am J Clin Oncol 28(6):638-9, 2005. e-Pub 2005. PMID: 16317281.
30. Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: What is the significance?. Int J Cancer 114(4):509-512, 2005. e-Pub 2005. PMID: 15578717.
31. Chadha MK, Kuvshinoff BW, Javle MM. Neoadjuvant Therapy for Gastric Cancer. Oncology (Williston Park) 19(9):1219-1227, 2005. e-Pub 2005. PMID: 16255136.
32. Chadha MK, LeVea C, Javle M, Kuvshinoff B, Vijaykumar R, Iyer R. Anaplastic pancreatic carcinoma. A case report and review of literature. JOP 5(6):512-515, 2004. e-Pub 2004. PMID: 15536293.
33. Javle M, Raghavan D. Radiotherapy and chemotherapy for invasive bladder cancer. Cancer Surv 31:149-60, 1998. e-Pub 1998. PMID: 15281322.
34. Raghavan D, Koczwara B, Javle M. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer 33(4):566-574, 1997. e-Pub 1997. PMID: 9274436.
35. Javle M, Raghavan D. Total androgen blockade for prostate cancer: the end does not justify the means. Cancer Treat Res 88:201-210, 1996. e-Pub 1996. PMID: 9239481.

Other Articles

1. Duda, DG, Javle, M A GOLP rush in biliary tract cancer. The lancet oncology 26(10):1265-1267, 2025. PMID: 40889501.
2. Duda, DG, Javle, M A GOLP rush in biliary tract cancer. The lancet oncology 26(10):1265-1267, 2025. PMID: 40889501.
3. Roa JC, García P, Kapoor VK, Maithel SK, Javle M, Koshiol J Gallbladder cancer. Nat Rev Dis Primers 8(1):69, 2022. PMID: 36302789.
4. Roa JC, García P, Kapoor VK, Maithel SK, Javle M, Koshiol J Publisher Correction: Gallbladder cancer. Nat Rev Dis Primers 8(1):75, 2022. PMID: 36400795.
5. Jain A, Javle M Personalized therapy for biliary tract cancer. Current Opinion in Oncology.

Editorials

1. Nassif, EF, Javle, M, Yap, TA. Poly(adenosine diphosphate ribose) polymerase inhibition in isocitrate dehydrogenase 1 and 2–mutant tumors. Cancer 131(10), 2025. PMID: 40323702.

Abstracts

1. Piha-Paul SA, Goel S, Liao C, Gabrail NY, Dayyani F, Ali Kazmi SM, Yuan Y, Lavasani SM, Fan J, Peng P, Sun C, Wang H, Hennessy K, Fu X, Ni S, Tan HX, Ngo B, Ru QC, Wu F, Javle MM. Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial. J Clin Oncol, 2023. e-Pub 2023.
2. Nottke A, Javle MM, Borad MJ, Azad NS, Brimble E, Martin RL, OBrien C, Lindsey S, Bachini M, Maithel SK. A novel patient-centric longitudinal data registry platform to generate insights into real-world cholangiocarcinoma (CCA) clinical practice. J Clin Onco, 2023. e-Pub 2023.
3. Moffat GT, Hu ZI, De Armas AD, Ross JS, Javle MM, Knox JJ. Characterizing KRAS allele variants within biliary tract cancers. J Clin Onco, 2023. e-Pub 2023.
4. Goyal L, Harding JJ, Ueno M, Lamarca A, Macarulla T, Yamamoto N, Hu J, Teufel M, Maerten A, Vogel A, Javle MM. A phase IIa/IIb, open-label trial of BI 907828, an MDM2–p53 antagonist, in patients with locally advanced/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2. J Clin Oncol, 2023. e-Pub 2023.
5. Eluri M, De Armas AD, Ross JS, Sharaf R, Pavlick DC, Chatterjee D, Javle MM. Clinical and mutational profiles of microsatellite instability (MSI-H) in intrahepatic cholangiocarcinoma (iCCA). J Clin Oncol, 2023. e-Pub 2023.
6. Tang T, De Armas AD, Ross JS, Pavlick DC, Sharaf R, Kaplan BG, Sokol E, Ahnert JR, Javle MM. Landscape of BRAF mutation classes in intrahepatic cholangiocarcinoma. J Clin Onco, 2023. e-Pub 2023.
7. Nelson BE, Roszik J, NOIA BARRETO CM, Nardo M, Ahmed J, Campbell E, Johnson A, Piha-Paul SA, Glitza IC, Weathers SS, Cabanillas ME, Javle MM, Meric-Bernstam F, Subbiah V. RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study. J Clin Oncol, 2023. e-Pub 2023.
8. Shroff RT, Guthrie KA, Scott AJ, Borad MJ, Goff LW, Matin K, Mahipal A, Kalyan A, Javle MM, Aghajanian C, Tan BR, Cheema PS, Patel AK, Iyer RV, Kelley RK, Thumar JR, El-Khoueiry AB, Chiorean E, Hochster HS, Philip PA. SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J Clin Oncol, 2023. e-Pub 2023.
9. Javle MM, Fountzilas C, Li D, Kankeu Fonkoua LA, Fan J, Peng P, Wang H, Ngo B, Sun C, Ru QC, Wu F, Mahipal A. Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis. J Clin Oncol, 2023. e-Pub 2023.
10. Javle MM. Overcoming Emerging Drug Resistance in Intrahepatic Cholangiocarcinoma. J Clin Oncol, 2022. e-Pub 2022.
11. Maithel SK, Javle MM, Mahipal A, Lin BS, Akce M, Switchenko JM, Rupji M, Cao HT, Cleary SP, Rocha FG. NEO-GAP: A phase II single-arm prospective feasibility study of neoadjuvant gemcitabine/cisplatin/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma. J Clin Oncol, 2022. e-Pub 2022.
12. Javle MM, Abou-Alfa GK, Macarulla T, Personeni N, Adeva J, Bergamo F, Malka D, Vogel A, Knox JJ, Evans TR, Dimova-Dobreva M, Harris WP, Saulay M, Engelhardt M, Braun S, Dit Busset MD, Borad MJ. Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01. 2022 ASCO Gastrointestinal Cancers Symposium, 2022. e-Pub 2022.
13. Javle MM. Moderated Panel Discussion with Drs. Kulik, Spencer, Lamarca, Rocha, Javle, 2022. e-Pub 2022.
14. Piha-Paul SA, Xu B, Singh Raghav KP, Meric-Bernstam F, Janku F, Dumbrava EE, Fu S, Karp DD, Ahnert JR, Conley AP, Mott F, Ajani JA, Hong DS, Fan Y, Peng P, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. J Clin Oncol, 2022. e-Pub 2022.
15. Amaria RN, Vining DJ, Kopetz S, Overman MJ, Javle MM, Antonoff M, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel KM, Wilson L, Fellman BM, Haymaker CL, Yuan Y, Forget M, Hwu P, Bernatchez C, Jazaeri AA. Efficacy and safety of autologous expanded tumor infiltrating lymphocytes (TILs) in multiple solid tumors. J Clin Onco, 2022. e-Pub 2022.
16. Upadhyay R, Ludmir EB, De B, Holliday E, Smith GL, Taniguchi CM, Das P, Minsky BD, Koong AC, Javle MM, Lee SS, Vauthey J, Tzeng CD, Cao HT, Koay EJ. Preservation of liver function with local radiation therapy in patients with metastatic intrahepatic cholangiocarcinoma with extrahepatic disease. J Clin Oncol, 2022. e-Pub 2022.
17. Ngoi N, Scholefield EL, Parini V, Huang RS, Janovitz T, Danziger N, Levy MA, Pant S, Javle MM, Ross JS, Ahnert JR. Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss), 2022. e-Pub 2022.
18. DiPeri TP, Newhook TE, Tzeng CD, Chun YS, Lee SS, Javle MM, Vauthey J, Tran Cao HS. Prognostic significance of serum CA 19-9 response and dynamics in patients with intrahepatic cholangiocarcinoma undergoing surgical resection, 2022. e-Pub 2022.
19. Patel H, Barrett A, Mauer E, Kato S, Leibowitz BD, Singhi AD, Javle MM, Lowy AM. Homologous recombination repair pathway alterations and their relationship to homologous recombination deficiency in advanced pancreatic cancer patients, 2022. e-Pub 2022.
20. Wang L, Singhal M, Eluri M, Valderrama A, Nepal B, Kamble S, Grabner M, Malhotra U, Siegel AB, Swami S, Javle MM. Health care resource utilization (HCRU) and costs in patients with biliary tract cancer (BTC) treated with systemic therapy in the United States (US). J Clin Onco, 2022. e-Pub 2022.
21. Eluri M, Hatia R, Javle MM, Hassan M. The association of family history of primary liver cancer with cholangiocarcinoma: USA case-control study. 2022 ASCO Gastrointestinal Cancers Symposium, 2022. e-Pub 2022.
22. Tang T, Ross JS, Ahnert JR, Javle MM. Genomic profile of intrahepatic cholangiocarcinoma with MTAP loss. J Clin Oncol, 2022. e-Pub 2022.
23. Abou-Alfa GK, Borbath I, Goyal L, Lamarca A, Macarulla T, Oh D, Roychowdhury S, Sadeghi S, Shroff RT, Li A, Soto J, Avogadri F, Dambkowski CL, Javle MM. PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement. J Clin Oncol, 2022. e-Pub 2022.
24. Valderrama A, Singhal M, Wang L, Nepal B, Kamble S, Grabner M, Malhotra U, Javle MM. Treatment patterns and clinical outcomes among patients with biliary tract cancers in a large commercially insured US population. 2022 ASCO Gastrointestinal Cancers Symposium, 2022. e-Pub 2022.
25. Meric-Bernstam F, Hanna DL, El-Khoueiry AB, Kang Y, Oh D, Chaves JM, Rha SY, Hamilton EP, Pant S, Javle MM, Singh Raghav KP, Fortenberry A, Gray T, Woolery J, Lee KW. Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study. J Clin Oncol, 2021. e-Pub 2021.
26. Javle MM, Kelley RK, Springfeld C, Abou-Alfa GK, Macarulla T, Tanasanvimon S, Goyal L, Borbath I, Bitzer M, Yong W, Philip PA, Alvarez-Gallego R, Pande A, Shepherd SP, Fontaine J, Roychowdhury S. A phase II study of infigratinib in previously treated advanced/metastatic cholangiocarcinoma with FGFR gene fusions/alterations. J Clin Oncol, 2021. e-Pub 2021.
27. Javle MM, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry AB, Yong W, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Shepherd SP, Moran S, Abou-Alfa GK. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. J Clin Onco, 2021. e-Pub 2021.
28. Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh D, Whisenant JR, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation. J Clin Oncol, 2021. e-Pub 2021.
29. Makawita S, Borad MJ, Carapeto F, Kwong L, Bekaii-Saab TS, Murugesan K, Ross JS, Danziger N, Israel MA, McGregor K, Janku F, Javle MM. IDH1 and IDH2 Driven Intrahepatic Cholangiocarcinoma (IHCC): A comprehensive genomic and immune profiling study. J Clin Oncol, 2021. e-Pub 2021.
30. Bajor DL, Gutierrez M, Vaccaro GM, Masood A, Brown-Glaberman UA, Grilley-Olson JE, Javle MM, Kindler HL, Gbolahan OB, Shields AF, Zalupski M, Schmitt MW, Coveler AL. Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC) (trial in progress). J Clin Oncol, 2021. e-Pub 2021.
31. Anne Piha-Paul SA, Xu B, Janku F, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Ahnert JR, Tsimberidou AM, Javle MM, Fan Y, Peng P, Levin WJ, Ngo B, Wang H, Sun C, Ru QC, Wu F. Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. J Clin Oncol, 2021. e-Pub 2021.
32. Javle MM, Bridgewater JA, Gbolahan OB, Jungels C, Cho MT, Papadopoulos KP, Thistlethwaite FC, Canon JR, Cheng L, Ioannidis S, Gogov S, Naing A. A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (Pts) with advanced biliary tract cancers. J Clin Oncol, 2021. e-Pub 2021.
33. Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, Braud FD, Prager GW, Greil R, Stein A, Fasolo A, M Schellens JH, Wen PY, Viele K, Boran AD, Gasal E, Burgess P, Ilankumaran P, Wainberg ZA. Dabrafenib plus trametinib in patients with BRAF V600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Onvol, 2020. e-Pub 2020. PMID: 32818466.
34. Sapisochin G, Javle M, Lerut J, Ohtsuka M, Ghobrial M, Hibi T, Kwan NM, Heimbach J. Liver Transplantation for Cholangiocarcinoma and Mixed Hepatocellular Cholangiocarcinoma: Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 104(6):1125-1130, 2020. e-Pub 2020. PMID: 32217937.
35. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng C, Lee JE, G Katz MH. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg, 2020. e-Pub 2020. PMID: 31895709.
36. Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh D, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol, 2020. e-Pub 2020. PMID: 32416072.
37. Pairawan S, Hess KR, Janku F, Sanchez NS, Mills Shaw KR, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res, 2020. e-Pub 2020. PMID: 31852833.
38. Pancreatic Cancer GDSRNMPOOSIACOPW. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clin Cancer Res, 2020. e-Pub 2020. PMID: 31871297.
39. Athauda A, Fong C, Lau DK, Javle M, Abou-Alfa GK, Morizane C, Steward K, Chau I. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. CANCER TREAT REV, 2020. e-Pub 2020. PMID: 32203843.
40. Overman M, Javle M, Davis RE, Vats P, Kumar-Sinha C, Xiao L, Mettu NB, Parra ER, Benson AB, Lopez CD, Munugalavadla V, Patel P, Tao L, Neelapu S, Maitra A. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer, 2020. e-Pub 2020. PMID: 32114502.
41. Makawita S, Kelley RK, Roychowdhury S, Weiss KH, Abou-Alfa GK, Macarulla T, Sadeghi S, Waldschmidt D, Zhu AX, Goyal L, Yong W, Borbath I, El-Khoueiry AB, Philip PA, Moran S, Ye Y, Soifer HS, Li G, Berman C, Javle MM, Cancer Center TUOTMA, Houston, TX, San Francisco UOC, Francisco S, CA, Cancer Hospital OSCCC, Columbus, OH, Heidelberg UH, Heidelberg, Germany, Cancer Center MSK, York N, NY, d’Hebron HV, Barcelona, Spain, Los Angeles UOCA, Monica S, CA, zu Köln KDU, Köln, Germany, Hospital MG, Boston, MA, Cancer Institute NU, Singapore, Singapore, Luc Bruxelles CUS, Brussels, Belgium, Cancer Center UNC, Angeles L, CA, Institute KC, Detroit, MI, Inc QED, Francisco S, CA, Cancer Center UOTMA, Houston, TX. Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions, 2020. e-Pub 2020.
42. Javle MM, Sadeghi S, El-Khoueiry AB, Goyal L, Philip PA, Kelley RK, Borbath I, Macarulla T, Yong W, Tanasanvimon S, Pande A, Li G, Howland M, Berman C, Abou-Alfa GK. A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions. J Clin Onco, 2020. e-Pub 2020.
43. Javle MM, Shaib WL, Braun S, Engelhardt M, Borad MJ, Abou-Alfa GK, Boncompagni A, Friedmann S, Gahlemann CG. FIDES-01, a phase II study of derazantinib in patients with unresectable intrahepatic cholangiocarcinoma (iCCA) and FGFR2 fusions and mutations or amplifications (M/A). J Clin Oncol, 2020. e-Pub 2020.
44. Xu S, Rao W, Zheng Y, Wang J, Hu W, Dong G, Wang J, Ren G, Shi J, Wang Y, Javle MM, Yao M. The landscape of MET mutations in Chinese biliary tract cancers. J Clin Oncol, 2020. e-Pub 2020.
45. Goyal L, Lamarca A, Strickler JH, Cecchini M, Ahn DH, Baiev I, Boileve A, Tazdait M, Hannan LM, Jia J, Marble HD, Barzi A, Sahai V, Lennerz JK, Kelley RK, Bekaii-Saab TS, Javle MM, Uboha NV, Harris WP, Hollebecque A. The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA). J Clin Onco, 2020. e-Pub 2020.
46. Varghese AM, Ang C, Dimaio CJ, Javle MM, Gutierrez M, Yarom N, Stemmer SM, Golan T, Geva R, Semenisty V, Khamaysi I, Ligresti R, Rotkopf S, Gabai-Malka R, Galun E, Shemi A, Schattner M, O'Reilly EM. A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT). J Clin Oncol, 2020. e-Pub 2020.
47. Javle MM, Sadeghi S, El-Khoueiry AB, Goyal L, Philip PA, Kelley RK, Borbath I, Macarulla T, Yong W, Tanasanvimon S, Pande A, Li G, Howland M, Berman C, Abou-Alfa GK. A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions. J Clin Onco, 2020. e-Pub 2020.
48. Sánchez NS, Kahle MP, Bailey AM, Wathoo C, Balaji K, Demirhan ME, Yang D, Javle M, Kaseb A, Eng C, Subbiah V, Janku F, Raymond VM, Lanman RB, Mills Shaw KR, Meric-Bernstam F. Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO PRECIS Oncol, 2019. e-Pub 2019. PMID: 32923868.
49. Ajani JA, Javle MM, Eng C, Fogelman DR, Anderson BD, Zhang C, Iizuka K, Cancer Center TUOTMA, Houston, TX, Cancer Center UOTMA, Houston, TX, Medical Oncology DOG, Cancer Center TUOTMA, Houston, TX, Theradex, Princeton, NJ, Pharma D, Inc, Tokushima, Japan. Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved tolerability, in patients with solid tumors, 2019. e-Pub 2019.
50. Janku F, Sen S, Pant S, Bramwell L, Subbiah V, Way T, Javle MM, Stone C, Prajapati B, Hagiwara S, Johansen M, Madden T, Maier G, Subach RA, Saeki K, Suzuki T, Wages DS, Wheeler CA, Falchook GS, Cancer Center TUOTMA, Houston, TX, Research Institute SC, Denver, CO, Cancer Center UOTMA, Houston, TX, Corporation F, Minato-Ku, Tokyo, Japan, Pharmaceuticals F, Cambridge, MA, FUJIFILM Pharmaceuticals USA, Inc, Cambridge, MA, FUJIFILM Pharmaceuticals USA, Inc, Cambridge, MA, FUJIFILM Pharmaceuticals USA, Inc, Brookline, MA, Doc Wages LLC, Southborough, MA. Phase 1/2 trial of FF-10502-01, a pyrimidine antimetabolite, in patients with advanced cholangiocarcinoma and solid tumors, 2019. e-Pub 2019.
51. Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarker. j.gastro, 2019. e-Pub 2019. PMID: 30836094.
52. Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarker. j.gastro, 2019. e-Pub 2019. PMID: 30836094.
53. Amaria RN, Bernatchez C, Forget M, Haymaker CL, Conley AP, Livingston J, Varadhachary GR, Javle MM, Maitra A, Tzeng CD, Hinchcliff E, Bayer V, Gasior Y, Hilton T, Celestino J, Rangel KM, Yuan Y, Lu KH, Hwu P, Jazaeri AA, Cancer Center TUOT-MA, Houston, TX, Cancer Center TUOTMA, Houston, TX, Medical Oncology DOS, Cancer Center TUOTMA, Houston, TX, Medical Oncology DOG, Cancer Center TUOTMA, Houston, TX, Cancer Center UOTMA, Houston, TX, Center MD, Houston, TX. Adoptive transfer of tumor-infiltrating lymphocytes in patients with sarcomas, ovarian, and pancreatic cancers. J Clin Oncol, 2019. e-Pub 2019.
54. Javle MM, Murugesan K, Shroff RT, Borad MJ, Abdel-Wahab R, Schrock AB, Chung J, Goyal L, Frampton GM, Kelley RK, Miller VA, Ross JS, Bekaii-Saab TS, Ali SM, Albacker LA, Cancer Center UOTMA, Houston, TX, Medicine F, Inc, Cambridge, MA, Cancer Center TUOTMA, Houston, TX, Cancer Center MC, Scottsdale, AZ, Hospital AU, Medicine FO, Assiut, Egypt, Hospital MG, Boston, MA, San Francisco UOC, Francisco S, CA, Medical University SU, Syracuse, NY, Clinic M, Phoenix, AZ. Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH). J Clin Oncol, 2019. e-Pub 2019.
55. Javle MM, Borbath I, Clarke SJ, Hitre E, Louvet C, Mercade TM, Oh D, Spratlin JL, Valle JW, Weiss KH, Berman C, Howland M, Ye Y, Cho T, Moran S, Abou-Alfa GK, Center MD, Houston, TX, Luc Bruxelles CUS, Bruxelles, Belgium, Sydney UO, Sydney, Australia, of Oncology NI, Budapest, Hungary, Montsouris IM, Paris, France, University Hospital VD, of Oncology VDI, Barcelona, Spain, University Hospital SN, Seoul, Korea S, Services AH, Edmonton, AB, Canada, Manchester/The Christie UO, Manchester, Kingdom U, Heidelberg UH, Heidelberg, Germany, Inc QED, Francisco S, CA, Cancer Center MSK, York N, NY. Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial. J Clin Oncol, 2019. e-Pub 2019.
56. Moss TJ, Ahnert JR, Oakley HD, Kahle M, Karp DD, Pant S, Jacob J, Raymond VM, Lanman RB, Kwong L, Routbort M, Soni N, Huang J, Javle MM, Meric-Bernstam F. Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120, 2019. e-Pub 2019.
57. Goyal L, Bahleda R, Furuse J, Valle JW, Moehler MH, Oh D, Chang H, Kelley RK, Javle MM, Borad MJ, Chen L, Uboha NV, Klumpen H, O'Dwyer PJ, Li D, Morizane C, Huang J, Bridgewate JA. FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. J Clin Oncol, 2019. e-Pub 2019.
58. Idris T, Barghash M, Kotrotsou A, Huang HJ, Subbiah V, Kaseb AO, Piha-Paul SA, Hong DS, Meric-Bernstam F, Javle MM, Janku F, Colen RR, Cancer Center TUOTMA, Houston, TX, Cancer Center TUOTMA, Houson, TX, Cancer Center UOTMA, Houston, TX. CT-based radiogenomic signature to identify isocitrate dehydrogenase (IDH)1/2 mutations in advanced intrahepatic cholangiocarcinoma, 2019. e-Pub 2019.
59. Bernard V, Kim DU, Lucas F, Castillo J, Allenson K, Mulu FC, Stephens BM, Huang J, Semaan A, Guerrero PA, Kamyabi N, Zhao J, Hurd MW, Koay EJ, Taniguchi CM, Herman JM, Javle M, Wolff R, Katz M, Varadhachary G, Maitra A, Alvarez HA. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. j.gastro, 2019. e-Pub 2019. PMID: 30240661.
60. Mohindroo C, Rogers JE, Hasanov M, Mizrahi J, Overman MJ, Varadhachary GR, Wolff RA, Javle MM, Fogelman DR, Pant S, McAllister F. A retrospective analysis of antibiotics usage and effect on overall survival and progressive free survival in patients with metastatic pancreatic cancer, 2019. e-Pub 2019.
61. Hasanov M, Mohindroo C, Rogers J, Prakash L, Overman MJ, Varadhachary GR, Wolff RA, Javle MM, Fogelman DR, Pant S, G Katz MH, Kim MP, Tzeng CD, McAllister F. The effect of antibiotic use on survival of patients with resected pancreatic ductal adenocarcinoma, 2019. e-Pub 2019.
62. Abdel-Wahab R, Liu S, Ross JS, Schrock AB, Ali SM, Cao J, Zhuang L, Lin J, Shroff RT, Javle MM, Wang K, Zhao H. Genomic diversity between Asian and United States intrahepatic cholangiocarcinoma patients, 2019. e-Pub 2019.
63. Abu-Gheida I, Patel A, Zaid M, Elganainy D, Javle MM, Singh Raghav KP, Vauthey J, Aloia TA, Tzeng CD, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong A, Krishnan S, Herman JM, Das P, Crane CH, Koay EJ. Outcomes and patterns of failures after hypofractionated radiation therapy for intrahepatic cholangiocarcinoma, 2019. e-Pub 2019.
64. Javle MM, Oh D, Ikeda M, Qin S, Yong W, Chao Y, McIntyre N, Hsieh C, Chow L, Chang A, McHale M, Lindmar B. TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs), 2018. e-Pub 2018.
65. Groisberg R, Hess KR, Hong DS, Heymach J, Naing A, Piha-Paul SA, Janku F, Javle MM, Hu MI, Conley AP, Meric-Bernstam F, Subbiah V. Outcomes of patients with gene fusion driven cancers treated on early phase clinical trials, 2018. e-Pub 2018.
66. Hecht J, Naing A, Falchook GS, Patel MR, Infante JR, Aljumaily R, Wong DJ, Autio KA, Wainberg ZA, Javle MM, Bendell JC, Pant S, Hung A, Vlasselaer PV, Leveque J, Oft M, Papadopoulos KP. Overall survival of PEGylated pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC), 2018. e-Pub 2018.
67. Pairawan SS, Hess KR, Janku F, Sanchez NS, Eng C, Damodaran S, Javle MM, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free circulating tumor DNA somatic alteration burden and its impact on survival in metastatic cancer, 2018. e-Pub 2018.
68. Mizrahi J, Javle MM, Xiao L, Varadhachary GR, Singh Raghav KP, Wolff RA, Shroff RT. A phase II study of ramucirumab for advanced, pre-treated biliary cancers, 2018. e-Pub 2018.
69. Pestana RC, Solis LM, Wang X, Abdel-Wahab R, Chen H, Foo WC, Kwong L, Javle MM. Immunoprofiling in intrahepatic cholangiocarcinoma (IHCC), 2018. e-Pub 2018.
70. Sanchez NS, Bailey AM, Wathoo C, Balaji K, Demirhan ME, Yang D, Kahle M, Kaseb AO, Javle MM, Eng C, Subbiah V, Janku F, Raymond VM, Lanman RB, Shaw KR, Meric-Bernstam F. Identification of actionable genomic alterations utilizing cfDNA, 2018. e-Pub 2018.
71. Gulhati P, Prakash L, G Katz MH, Wang X, Javle MM, Shroff RT, Fogelman DR, Lee JE, Tzeng CD, Lee JH, Weston B, Tamm EP, Bhosale P, Koay EJ, Maitra A, Wang H, Wolff RA, Varadhachary GR. First line gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma, 2018. e-Pub 2018.
72. Abou-Alfa GK, Valle JW, Kelley RK, Goyal L, Shroff RT, Javle MM, Borad MJ, Cleary JM, El-Khoueiry AB, Bendell JC, Macarulla TM, Vogel A, Korth C, Jiang L, Gliser C, Wu B, Agresta SV, Pandya SS, Zhu AX. ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation, 2018. e-Pub 2018.
73. Hecht J, Naing A, Falchook GS, Patel MR, Infante JR, Aljumaily R, Lee Wong DJ, Autio KA, Wainberg ZA, Javle MM, Bendell JC, Pant S, Hung A, Vlasselaer PV, Oft M, Papadopoulos KP. Overall survival of PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC), 2018. e-Pub 2018.
74. George B, Greenbowe JR, Hendifar AE, Golan T, Javle MM, Maitra A, Bahary N, Schrock AB, Stephens PJ, Miller VA, Ross JS, Yakirevich E, Ritch PS, Thomas JP, Ali SM, Singhi AD. Comprehensive genomic profiling (CGP) in KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC), 2018. e-Pub 2018.
75. Marcus R, Lillemoe HA, Abdel-Wahab R, Shroff RT, Javle MM, Aloia TA. The impact of tumor genomic profile on the effectiveness of adjuvant chemotherapy in resectable intrahepatic cholangiocarcinoma, 2018. e-Pub 2018.
76. Golan T, Varadhachary GR, Sela T, Fogelman DR, Halperin N, Shroff RT, Halparin S, Xiao L, Aderka D, Maitra A, Ackerstein A, Wolff RA, Shacham-Shmueli E, Javle MM, Center SM, Gan R, Israel. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer, 2018. e-Pub 2018.
77. Abdel-Wahab R, Ali SM, Borad MJ, Shroff RT, Kwong L, Vauthey J, Koay EJ, Zuo M, Rashid A, Schrock AB, Ross JS, Bekaii-Saab TS, Javle MM. Variations in DNA repair genomic alterations and tumor mutation burden in biliary tract cancer (BTC) subtypes, 2018. e-Pub 2018.
78. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Singh Raghav KP, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. A phase II trial of gemcitabine (G), cisplatin (C), and nab-paclitaxel (N) in advanced biliary tract cancers (aBTCs): Updated survival analysis, 2018. e-Pub 2018.
79. Fogelman DR, Townson SM, Varadhachary GR, Javle MM, Shroff RT, Wolff RA, Overman MJ, Ho L, Haras AV, Lustig TM, Sorani E, Lane ME, Kaufman DR, Yao JC. A pilot study to assess the efficacy, safety, and pharmacodynamic effects of pembrolizumab and BL-8040 in patients with metastatic pancreatic cancer, 2018. e-Pub 2018.
80. Groisberg R, Hong DS, Janku F, Tsimberidou AM, Javle MM, Meric-Bernstam F, Subbiah V. Clinical next generation sequencing for precision oncology in rare cancers, 2017. e-Pub 2017.
81. Shroff RT, Borad MJ, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Singh Raghav KP, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Javle MM. A phase II trial of gemcitabine (G), cisplatin (C), and nab-paclitaxel (N) in advanced biliary tract cancers (aBTCs). J Clin Oncol, 2017. e-Pub 2017.
82. JAVLE M. Oral Abstract Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract, 2017. e-Pub 2017.
83. Jain A, Shroff RT, Kelley RK, Kaseb AO, Wang Y, Abdel-Wahab R, Ahn DH, Bocobo AG, Meric-Bernstam F, Isaacs R, Bekaii-Saab TS, Javle MM, GI. FGFR pathway genetic aberrations in cholangiocarcinoma: Demographics and experience with targeted therapy. J Clin Oncol, 2016. e-Pub 2016.
84. Infante JR, Naing A, Papadopoulos KP, Autio KA, Ott PA, Wong DJL, Falchook GS, Patel MR, Pant S, Whiteside M, Bendell JC, Bauer TM, Janku F, Javle MM, Hong DS, Oft M. A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. J Clin Oncol 33(15):3017, 2016. e-Pub 2016.
85. Kato S, Janku F, Piha-Paul SA, Naing A, Karp DD, Tsimberidou AM, Subbiah V, Zinner R, Hwu W, Javle MM, Parkhurst KL, Ramzanali NM, Kurzrock R, Meric-Bernstam F, Chae YK, Kim K, Falchook GS. Phase 1 study of combination vemurafenib, carboplatin, and paclitaxel in patients (pts) with BRAF-mutant advanced cancer. ASCO Meeting Abstracts 33(15_suppl):105, 2016. e-Pub 2016.
86. Murthy R, Rachakonda V, Mahvash A, Huang SY, Sabir SH, Subbiah V, Janku F, Kaseb AO, Javle MM, Murthy A. Percutaneous transhepatic biliary drainage in hepatopancreaticobiliary cancer: Contemporary efficacy. ASCO Meeting Abstracts 34(15_suppl):e21637, 2016. e-Pub 2016.
87. Overman MJ, Lopez CD, Benson AB, Neelapu SS, Mettu NB, Ko AH, Chung VM, Nemunaitis JJ, Reeves JA, Bendell JC, Philip PA, Dalal R, Fardis M, Greer J, Wang X, Inamdar S, Lannutti BJ, Rothbaum W, Izumi R, Javle MM. A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastiatic pancreatic cancer (mPC). ASCO Meeting Abstracts 34(15_suppl):4130, 2016. e-Pub 2016.
88. Ahn DH, Javle MM, Ahn C, Jain A, Mikhail S, Shroff RT, Ciombor KK, Noonan AM, Wu CS, Chen JL, Bakaii-Saab TS. Next-generation sequencing (NGS) survey of biliary tract cancer (BTC) to reveal the association between tumor somatic variants and chemotherapy resistance. ASCO Meeting Abstracts 34(15_suppl):4079, 2016. e-Pub 2016.
89. Jain A, Schroff RT, Kelley RK, Kaseb AO, Wang Y, Abdel-Wahab R, Ahn DH, Bocobo AG, Meric-Bernstam F, Isaacs R, Bekaii-Saab TS, Javle MM. FGFR pathway genetic aberrations in cholangiocarcinoma: Demographics and experience with targeted therapy. ASCO Meeting Abstracts 34(15_suppl):109, 2016. e-Pub 2016.
90. Crane CH, Tao R, Bhosale P, Javle MM, Shroff RT, Aloia TA, Kaseb AO, Koay EJ, Bishop AJ, Swanick CW, Hong TS, Das P, Krishnan S. Effect of ablative radiotherapy on survival in patients with inoperable intrahepatic cholangiocarcinoma: A dose response analysis. J Clin Oncol 34(4):294, 2016. e-Pub 2016.
91. Ahn DH, Ahn C, Jain A, Mikhail S, Wu CSY, Goldberg RM, Ciombor KK, Noonan AM, Sadavartia P, Shroff RT, Javle MM, Chen JL, Bekaii-Saab TS. Next Generation Sequencing (NGS) to reveal mutations in IDH1 and its effect on patient (pt) outcomes in advanced biliary tract cancer (aBTC) who received gemcitabine and cisplatin (GC). J Clin Oncol 34(4):287, 2016. e-Pub 2016.
92. Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Lowery MA, Abou-Alfa GK, Ahn DH, Jain A, Bekaii-Saab TS, Friedman E, Javle MM. Overall survival and clinical characteristics of BRCA germline/somatic cholangiocarcinoma (CCA). J Clin Oncol 34(4):244, 2016. e-Pub 2016.
93. Wang XS, Shi Q, Dougherty PM, Eng C, Mendoza TR, Williams LA, Fogelman DR, Cleeland CS. Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology 90(3):127-35, 2016. e-Pub 2016.
94. Gulhati P, Raghave KPS, Shroff RT, Varadhachary GR, Kopetz S, Javle MM, Qiao W, Wang HM, Morris J, Wolff RA, Overman MJ. Phase II study of bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater. J Clin Oncol 34(4):144, 2016. e-Pub 2016.
95. Hong TS, Wo JYL, Ben-Josef E, McDonnell E, Drapek LC, Blaszkowsky LS, Kwak EL, Clark JW, Goyal L, Ryan DP, Javle MM, Arellano R, Wolfgang JA, Mullen JT, Ferrone C, Tanabe K, DeLaney TF, Crane CH, Zhu AX. A multi-institutional phase II study of high-dose hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long-term outcomes in patients (pts) with hepatocellular carcinoma (HCC). J Clin Oncol 34(4):376, 2016. e-Pub 2016.
96. Javle MM, Rashid A, Kar SP, Schalper K, Wang N, Peto M, Vauthey JN, Aloia TA, De Aretxabala X, Mills GB, Spellman P, Roa I. Identification of unique somatic mutations with functional relevance through genetic characterization of gallbladder cancer (GB ca). J Clin Oncol 31(4):214, 2016. e-Pub 2016.
97. Javle MM, Shroff RT, Zhu A, Sadeghi S, Choo S, Borad MJ, Lowery MA, El-Khoueiry A, Macurulla T, Philip PA, Oh DY, Van Cutsem E, Yeh KH, Isaacs R, McGarry C, Sen S, Bekaii-Saab TS. A phase 2 study of BGJ398 in patients (pts) with advanced or metastiatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. J Clin Oncol 34(4):335, 2016. e-Pub 2016.
98. Shalaby AS, Botrus G, Kaseb AO, Li D, Abdel-Wahab R, Wolff RA, Javle MM, Hawk E, Hassan M. The protective effect of physical activity on risk of hepatocellular carcinoma in USA. ASCO Meeting Abstracts 34(15_suppl):e15642, 2016. e-Pub 2016.
99. Ross JS, Wang K, Javle MM, Catenacci DVT, Shroff RT, Ali SM, Elvin JA, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stepens PJ, Meric-Bernstam F. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations. J Clin Oncol 33(15):4009, 2015. e-Pub 2015.
100. Al-Shamsi HO, Barrera CD, Surapaneni R, Kang H, Shroff RT, Janku F, Krishnan S, Zuo MX, Wolff RA, Kaseb AO, Thomas MB, Siegel AB, Javle MM. HER2/neu-directed therapy for biliary tract cancer. J Clin Oncol 33(15):e15137, 2015. e-Pub 2015.
101. Goldstein JB, NOgueras-Gonzalez GM, Javle MM, Katz MHG, Varadhachary GR, Fogelman DR, Overman MJ, Wolff RA, Shroff RT. A retrospective single institution review of 90 pancreatic adenosquamous cancer (PASC) patients (pts). J Clin Oncol 33(15):4125, 2015. e-Pub 2015.
102. Hong TS, Wo JYL, Yeap BY, Ben-Josef E, McDonnell EI, Drapek LC, Blaszhkowsky LS, Kwak EL, Clark JW, Goyal L, Ryan DP, Javle MM, Wolfgang JA, Arellano R, Mullen JT, Ferrone C, Tanabe K, DeLaney TF, Crane CH, Shu AX. Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long term outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC). J Clin Oncol 33(15):4020, 2015. e-Pub 2015.
103. Crane CH, Chanda AS, Koay EJ, Varadhachary GR, Das P, Javle MM, Suh Y, Wolff RA, Fleming JB, Katz MHG, Fogelman DR, Shroff RT, Lee JE, Krishnan S. Effect of dose-escalation of IMRT for unresectable pancreatic cancer 1 cm away from the luminal mucosa on long-term survival. J Clin Oncol 33(3):354, 2015. e-Pub 2015.
104. Rogers JE, Nguyen V, Nogueras-Gonzalez GM, Ch C, Das P, Krishnan S, Law L, Javle MM, Kaseb AO, Shroff RT. Charterization of unresectable cholangiocardinoma patients treated with or without chemoradiation. J Clin Oncol 33(3):403, 2015. e-Pub 2015.
105. Ross JS, Wang K, Thomas Catenacci DV, Chmielecki J, Ali SM, Elvin JA, Yelensky R, Lipson D, Hawryluk MJ, Miller VA, Stephens PJ, Javle MM. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations, 2015. e-Pub 2015.
106. Anand D, Churi C, Rashid A, Shroff RT, Zuo MX, Conrad C, Vauthey JN, Javle MM. BAP1 mutation-associated cholangiocarcinoma: An aggressive disease. J Clin Oncol 33(3):420, 2015. e-Pub 2015.
107. Goldstein JB, Tang C, Hong DS, Subbiah V, Janku F, Hess KR, Fu SQ, Karp DD, Naing A, Tsimberidou AM, Wheler JJ, Zinner R, Javle MM, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center. J Clin Oncol 33(3):320, 2015. e-Pub 2015.
108. Golan T, Sella T, Javle MM, Borgida A, O'Reilly EM, Kelsen DP, Epelbaum R, Kindler HL, Katz MHG, Gallinger S. Overall survival and clinical characteristics in BRCA mutation carriers with stage I/II pancreatic cancer (PC). J Clin Oncol 33(3):287, 2015. e-Pub 2015.
109. Varadhachary GR, Fleming JB, Crane, Ch, Fogelman DR, Shroff RT, Lee JE, Lee JH, Tamm EP, Bhosale P, Das P, Krishman S, Javle MM, Weston B, Wang HM, Wolff RA, Katz MGH. Phase II study of preoperation mFOLFIRNOX and chemoradiation for high-risk resectable and borderline resectable pancreatic adenocarcinoma. J Clin Oncol 33(3):362, 2015. e-Pub 2015.
110. Ross JS, Wang K, Catenacci DVT, Chmielecki J, Ali AM, Elvin JA, Yelensky R, Lipson D, Hawryluk MJ, Miller VA, Stephens PJ, Javle MM. Comprehensive genomic profiling of biliary tract cancers tumor-specific differences and genomic alterations. ASCO Meeting Abstracts 33(3_suppl):231, 2015. e-Pub 2015.
111. Shroff RT, Churi C, Rashid A, Mishra L, Zuo MX, Kaseb AO, Janku F, Aloia TA, Vauthey JN, Curley SA, Javle MM. Next-generation sequencing yields promising targets in advanced cholangiocarcinoma (CCA). J Clin Oncol 32(3):209, 2014. e-Pub 2014.
112. Stephens P, Wang K, Palma NA, Chmielecki J, Shroff RT, Churl C, Frampton GM, ALi SM, Javle MM, Ross JS. Comprehensive genomic profiling of gallbladder adenocarcinoma and frequent genomic-derived targets of therapy. J Clin Oncol 32(15):4142, 2014. e-Pub 2014.
113. Fogelman DR, Khalil MA, Hassan M, Garg N, Javle MM, Katz MHG, Holmes HM, Abbruzzese JL. The effect of anti-IGF1 therapy on muscle mass in metastatic pancreatic cancer. J Clin Oncol 31(15):4064, 2013. e-Pub 2013.
114. Aly M, Sahin IH, Li DH, Khalil MF, Chang P, Fogelman DR, Javle MM, Abbruzzese JL, Hassan M. Pancreatic injury, genetic variation of PNPLA3, and risk of pancreatic cancer. J Clin Oncol 31(4):141, 2013. e-Pub 2013.
115. Tanasanvimon S, Rashid A, Wongkham S, Churi C, Tong ZM, Fogelman DR, Silsirivanit A, Blechacz B, Klaikaew N, Bhudhisawasdi V, Vauthey JN, Javle MM. Comparison of microRNA (MiRNA) expression profiles between opisthorchis viverrini-associated cholangiocarcinoma (OV-CCA) and non-opisthorchis viverrini-associated cholangiocarcinoma (non-OV CCA). J Clin Oncol 31(4):206, 2013. e-Pub 2013.
116. Javle MM, Rashid A, Kar SP, Schalper K, Wang N, Peto M, J-N V, Aloia TA, De Aretxabala X, Mills GB, Spellman P, and Roa I. Identification of unique somatic mutations with functional relevance through genetic characterization of gallbladder cancer (GB ca). ASCO Meeting Abstracts 31(4_suppl):214, 2013. e-Pub 2013.
117. Aly M, Sahin IH, Li D, Khalil MF, Chang P, Fogelman DR, Javle MM, Abbruzzese JL, and Hassan M. Pancreatic injury, genetic variation of PNPLA3, and risk of pancreatic cancer. ASCO Meeting Abstracts 31(4_suppl):141, 2013. e-Pub 2013.
118. Fogelman DR, Wang XS, Hassan M, Li D, Javle MM, Katz MHG, Overman MJ, Varadhachary GR, Shroff RT, Wolff RA, and Abbruzzese JL. Can we identify patients with cancer at high risk for cachexia? A prospective study in pancreatic cancer (PC). ASCO Meeting Abstracts 30(4_suppl):219, 2012. e-Pub 2012.
119. Skinner HD, Javle MM, Wolff RA, Clemons MV, Munsell MF, Delcos ME, Fleming JB, Das P, Crane CH, and Krishnan S. Phase I trial of radiotherapy with concurrent bevacizumab, erlotinib, and capecitabine for locally advanced pancreatic cancer (LAPC). ASCO Meeting Abstracts 30(4_suppl):254, 2012. e-Pub 2012.
120. Javle MM, Tan D, Li Y, Kar SP, Baladandayuthapani V, Dong X, Weatherly J, Krishnan S, T-CJ H, Fogelman DR, Abbruzzese JL, Wolff RA, Li D. Transforming growth factor (TGF) beta pathway and clinical outcome of pancreatic cancer. ASCO Meeting Abstracts 30(4_suppl):201, 2012. e-Pub 2012.
121. Van Loon K, Kim GP, Espinoza AM, Fogelman DR, Iyer RV, Picozzi VJ, Wolff RA, Javle MM, and Ko AH. A pooled analysis of phase II trials of gemcitabine (GEM) containing doublets plus bevacizumab (BEV): Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer (APC)?. ASCO Meeting Abstracts 30(15_suppl):4038, 2012. e-Pub 2012.
122. Javle MM, Shroff RT, Varadhachary GR, Wolff RA, Fogelman DR, Bhosale P, Wang X, Kar SP, Overman MJ, Sathyanarayanan S, Ayers M, Mauro DJ, and Abbruzzese JL. Tumor IGF-1 expression as a predictive biomarker for IGF1R-directed therapy in advanced pancreatic cancer (APC). ASCO Meeting Abstracts 30(15_suppl):4054, 2012. e-Pub 2012.
123. Tanasanvimon S, Garg N, Viswanathan C, Javle MM, Truong M, Kaur H, Garrett CR. Prevalence of recurrent thrombosis in cancer patients with isolated gonadal vein thrombosis: A retrospective study. ASCO Meeting Abstracts 30(15_suppl):e19645, 2012. e-Pub 2012.
124. Finn RS, Javle MM, Tan BR, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Anderson L, Christy-Bittel JL, Barrett E, Guthrie K, Litwiller KS, and Bekaii-Saab TS. A phase I study of MEK inhibitor MEK 162 (ARRY-438162) in patients with biliary tract cancer. ASCO Meeting Abstracts 30(4_suppl):220, 2012. e-Pub 2012.
125. Weatherly J, Eckmann K, Patel D, Landgraf AN, Slade JH, Wolff RA, Lin E, and Javle MM. Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: A retrospective analysis. ASCO Meeting Abstracts 29(4_suppl):271, 2011. e-Pub 2011.
126. Fogelman DR, Wang XS, Hassan M, Li D, Javle MM, Varadhachary GR, Shroff RT, Overman MJ, Wolff RA, Abbruzzese JL. Relative value of serum cytokines and clinical factors in predicting weight loss in advanced pancreatic cancer (PC). ASCO Meeting Abstracts 29(4_suppl):208, 2011. e-Pub 2011.
127. Huang TJ, Li D, Li Y, Kar SP, Krishnan S, Abbruzzese JL, Wolff RA, and Javle MM. Study of genotypic variations and protein expression of the xCT subunit of cystine/glutamate transporter in pancreatic cancer. ASCO Meeting Abstracts 29(4_suppl):210, 2011. e-Pub 2011.
128. Skinner HD, Sharp HJ, Kaseb AO, Javle MM, Vauthey J, Abdalla EK, Delclos ME, Das P, Crane CH, and Krishnan S. Dose-escalated external beam radiotherapy in unresectable hepatocellular carcinoma. ASCO Meeting Abstracts 29(4_suppl):267, 2011. e-Pub 2011.
129. Javle MM, Varadhachary GR, Fogelman DR, Shroff RT, Overman MJ, Ukegbu L, Bekele BN, Kar SP, Wolff RA, and Abbruzzese JL. Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer. ASCO Meeting Abstracts 29(15_suppl):4026, 2011. e-Pub 2011.
130. Bhadkamkar NA, Kar SP, Weatherly J, Garrett CR, Vauthey J, Kaseb AO, Das P, and Javle MM. The role of multimodality therapy (MMT) in unresectable hilar cholangiocarcinoma (UHC). ASCO Meeting Abstracts 29(15_suppl):e14626, 2011. e-Pub 2011.
131. Kar SP, Bhosale P, Overman MJ, Weatherly J, Xiao L, Wolff RA, Javle MM. Role of anticoagulation (AC) in patients with advanced pancreatic cancer (APC) with splanchnic venous thrombosis (SVT). ASCO Meeting Abstracts 29(15_suppl):e14622, 2011. e-Pub 2011.
132. Shroff RT, Javle MM, Li D, Wolff RA, Mauro DJ, Naumov G, Nebozhyn M, Zhang T, Li Y, and Sathyananrayanan S. Comprehensive analysis of potential predictive biomarkers for insulin-like growth factor type-1 receptor _IGF-1R) targeted therapy in pancreatic cancer. ASCO Meeting Abstracts 29(15_suppl):4052, 2011. e-Pub 2011.
133. Khushalani NI, Yang G, Tan W, Miecznikowski J, Wang D, Iyer RV, Yendamuri SS, Nwogu CE, Nava HR, Javle MM. Gene expression profile (GEP) for the prediction of pathologic complete response (pCR): Preliminary data from a neoadjuvant study of capecitabine (C), oxaliplatin (OXP), and radiation (RT) for esophageal cancer (EC). J Clin Oncol 28(15_suppl):4100, 2010. e-Pub 2010.
134. Iyer RV, Fetterly GJ, Javle MM, Tan W, Wilding GE, Muindi J, Fakih M, Ramnath N, Johnson CS, Trump DL. Enhanced gemcitabine (G) exposure in combination with escalating doses of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] (P) in patients with advanced malignancies. J Clin Oncol 28(15_suppl):4039, 2010. e-Pub 2010.
135. Khushalani NI, Fetterly GJ, Iyer RV, Litwin A, Brady W, Javle MM. Phase I study of sunitinib with irinotecan/5-fluorouracil/ leucovorin (FOLFIRI) for advanced gastroesophageal cancers. J Clin Oncol 28(15_suppl):TPS201, 2010. e-Pub 2010.
136. Javle MM, Varadhachary GR, Shroff RT, Bhosale P, Overman MJ, Weatherly J, Wolff RA, Abbruzzese JL. Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer. J Clin Oncol 28(15_suppl):4039, 2010. e-Pub 2010.
137. Kaseb AO, Morris J, Hassan M, Iwasaki M, Deaton L, Javle MM, Garrett-Mayer E, Onicescu G, Abbruzzese JL, Thomas MB. Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study. J Clin Oncol 28(15_suppl):4046, 2010. e-Pub 2010.
138. Huang TJ, Li D, Weatherly J, Tang H, Gout PW, Wolff RA, Abbruzzese JL, Javle MM. Prognostic significance of xCT gene single nucleotide polymorphisms (SNPs) in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (GEM) plus platinum analogues (PLAT). J Clin Oncol 28(15_suppl):4065, 2010. e-Pub 2010.
139. Vaccaro V, Fleming JB, Wolff RA, Evans DB, Tamm EP, Crane CH, Javle MM, Abbruzzese JL, Lee JE, Varadhachary GR. Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms. J Clin Oncol 28(15_suppl):4113, 2010. e-Pub 2010.
140. Shroff RT, Javle MM, Krishnan S, Cantor SB, Lee JE, Fleming JB, Varadhachary GR, Abbruzzese JL, Wolff RA, Elting LS. Cost-effectiveness of neoadjuvant (NeoAdj) versus adjuvant (Adj) therapies for resectable pancreatic cancer (PC). J Clin Oncol 28(15_suppl):4125, 2010. e-Pub 2010.
141. Bhadkamkar NA, Javle MM, Wolff RA, Payne WD, Tan D. Osteoclastic giant cell tumor of the pancreas: A distinct clinical and pathologic entity. J Clin Oncol 28(15_suppl):e14648, 2010. e-Pub 2010.
142. Kaseb AO, Iwasaki M, Javle M, Onicescu G, Garrett-Mayer E, Abbruzzese JL, Thomas MB. Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 27(15S):4522, 2009. e-Pub 2009.
143. Javle MM, Xiong H, Reddy S, Bhosale P, Davis D, Varadhachary G, Fogelman D, Kaseb A, Wolff RA, JLal A. Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: The results of two prospective phase II studies. J Clin Oncol 27(15S):4621, 2009. e-Pub 2009.
144. Javle MM, Okazaki T, Wolff RA, Varadhachary G, Ho L, Crane CH, San Miguel A, Evans D B, Abbruzzese JL, Li D. Combined effect of single nucleotide polymorphisms (SNPs) of gemcitabine metabolic genes on pancreatic cancer survival and drug toxicity. Proc GI-ASCO(126), 2008. e-Pub 2008.
145. Settle SH, Crane H, Das P, Varadhachary G, Tamm EP, Javle M, Hodges JC, Krishnan S, Evans DB, Wolff RA. Novel use of focal high-dose IMRT for borderline resectable pancreatic cancer. Proc GI-ASCO(203), 2008. e-Pub 2008.
146. Hammad N, Philip PA, Shields AF, Abbruzzese JL, Kaseb AO, Javle MM, Varadhachary GR, Wolff, RA, Sarkar FH, El-Rayes BF. A phase II study of isoflaavone (Novasoy), gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer. Proc GI-ASCO(262), 2008. e-Pub 2008.
147. Bharthuar, Khoury T, Baer MR, Black J, Oseroff A, Khushalani N, Javle M, Nava H, Iyer R. BCRP expression in upper gastrointestinal malignancies. Proc GI-ASCO, 2008. e-Pub 2008.
148. Pande AU, Iyer R, Nava H, Yang G, Nwogu C, Schiff M, Levea C, Black J, Javle M. Gefitinib (ZD1839) with oxaliplatin and radiotherapy (RT) for esophageal carcinoma (EC). Proc GI- ASCO:#68, 2007. e-Pub 2007.
149. Chadha MK, Lin P, Javle M, Iyer R, Driscoll D, Nava H, Levea C, Yang G. Cytokeratin (CK) staining to predict residual disease in patients undergoing neoadjuvant chemoradiation (Neo-CRT) for esophageal cancer. Proc GI-ASCO:#23, 2007. e-Pub 2007.
150. Agrawal S, Kuvshinoff BW, Khoury T, Yu J, Javle MM, LeVea C, Groth J, Coignet LJ, Gibbs JF. CD24 expression is an independent prognostic marker in cholangiocarcinoma. Proc GI-ASCO:#215, 2007. e-Pub 2007.
151. Javle M, Iyer RV, Yu J, Wilkinson DQ, Nava HR, Phelan JT, Litwin AM, Haney JM, Gibbs JF, Kuvshinoff BW. Phase II Study of Gemcitabine (GEM), Capecitabine (CAP) and Bevacizumab (BV) in Advanced Pancreatic Cancer (APC). Proc Am Soc Clin Oncol. (poster presentation), 2006. e-Pub 2006.
152. Ashraf S, Andrews C, Kuvshinoff B, Pande A, Javle M. Surgical resection for pancreatic cancer: Correlates of margin positivity. Proc Am Soc Clin Oncol. (poster presentation):#4097, 2006. e-Pub 2006.
153. Foster JM, Black J, LeVea C, Khoury T, Javle M, Kuvshinoff B. EGF pathway activation in hepatocellular carcinoma is a diagnostic predictor of survival and a potential target for biologic therapy. Proc GI Am Soc Clin Oncol (poster presentation) 212:191, 2006. e-Pub 2006.
154. Javle M, Iyer R, OMalley L, Yang G, Lawrence D, Nwogu CE. Phase I study of Capecitabine, Oxaliplatin and radiotherapy for locally advanced esophageal cancer (LAEC). Proc GI Am Soc Clin Oncol (poster presentation) 58:113, 2006. e-Pub 2006.
155. O’Connor BM, Agrawal JC, Lombardo CE, Nwogu R, Iyer V, Yang GY, Nava HR, Javle M. Concurrent oxaliplatin, 5-fluorouracil (5-FY), and radiotherapy for the treatment of locally advanced esophageal carcinoma. Proc GI Am Soc Clin Oncol (poster presentation) 57:113, 2006. e-Pub 2006.
156. Javle M, Iyer R, Yu J, Phelan J, Wallace P, Wilkinson D, Nava H, Haney J, Kuvshinoff B, Gibbs J. Gemcitabine, Capecitabine and Bevacizumab: Phase II study for advanced pancreatic cancer (APC) patients with good performance status (PS). Proc GI Am Soc Clin Oncol (poster presentation) 117:143, 2006. e-Pub 2006.
157. Javle M, Johnson CS, Muindi JR, W-D Y, Pendyala L, Creaven P, Ross M, Brady WE, Ramnath N, Fakih MG, Smith P, Iyer RV, Trump DL. Phase I, pharmacokinetic (PK), pharmacodynamic study of paricalcitriol [19-NOR-1 alpha, 25-(OH)2 D2] in combination with Gemcitabine [2,2 difluorodeoxyctyhidine] in patients with advanced malignancies. Proceedings of the 13th Workshop on Vitamin D, (poster presentation):177 (abstract #180), 2006. e-Pub 2006.
158. Javle M, Smith P, Iyer R, OMalley L, Flaherty L, Nwogu C, Nava H, Yang G, Pendyala L. Phase I, pharmacokinetic (PK), pharmacodynamic study of neoadjuvant capecitabine (CB), oxaliplatin (OX) and radiotherapy (RT) for locally advanced esophageal cancer (LAEC). Proc Am Assoc Cancer Res 47:94 (abstract 403), 2006. e-Pub 2006.
159. Creaven PJ, Javle M, Pendyala L, Smith P, Noel DC, Iyer RV, Lawrence DD, Rustum YM. Celecoxib in combination with irinotecan (CPT-11), 5-fluorouracil and leucovorin in patients with advanced cancer: A phase I, pharmacokinetic study. Proc Am Soc Clin Oncol 23:2092, 2005. e-Pub 2005.
160. Ailawadhi S, Khoury T, Levea C, Javle M, Kuvshinoff B, Okada H, Black J, Brattain M. Intestinal trefoil factor (TFF-3) expression and correlation with other signaling proteins in cholangiocarcinoma. Proc GI Am Soc Clin Oncol, 2005. e-Pub 2005.
161. Foster J, Black J, Khoury T, Levea C, Donohue K, Chadha K, Gibbs J, Javle M. COX-2 expression and activation of EGFR pathway are common in hepatocellular carcinoma. Proc GI Am Soc Clin Oncol, 2005. e-Pub 2005.
162. Chadha K, Khoury T, Levea C, Nagase H, Okada H, Tan D, Javle M. Intestinal trefoil factor expression in hepatocellular carcinoma. Proc GI Am Soc Clin Oncol:(abstr. 119), 2005. e-Pub 2005.
163. Javle M, Yu J, Chadha M, Khoury T, Levea CM, Gibbs JF, Iyer RV, Oleszek D, Brattain MG. MAPK activation predicts poor survival after pancreatico-duodenectomy. Proc Am Soc Clin Oncol:(abst. 9578), 2005. e-Pub 2005.
164. Iyer RV, Gibbs J, Kuvshinoff J, Fakih M, Soehnlein N, Lawrence D, Kepner J, Javle M. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and gall bladder carcinoma. Proc GI Am Soc Clin Oncol:(abstr. 4230), 2005. e-Pub 2005.
165. Senzer N, Hanna H, Chung T, Nemunaitis A, Rosemurgy A, Chang K, Javle M, Reid T, Waxman I, Hecht JR. Completion of dose escalation component of phase II study of TNFerade combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC). Proc GI Am Soc Clin Oncol:(abstr. 4097), 2005. e-Pub 2005.
166. Beer TM, Javle M, Henner WD, Trump DL. Pharmacokinetics (PK) and tolerability of DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Research 64(7S):91-92, 2004. e-Pub 2004.
167. Javle M, Khemka S, Donohue K, Demmy T, Yang G, Smith J, Nava H, Douglass HO. The role of surgery in the management of loco-regional esophageal cancer. 2004 Gastrointestinal Cancer Symposium:80, 2004. e-Pub 2004.
168. Wilkinson NW, Smiley S, Roukhadze E, Hisakazu H, Driscoll D, Geradts J, Javle M, Brattain M. Epidermal growth factor receptor (EGFR) expression correlates with histologic grade in adenocarcinoma of the esophagus. Proc Am Soc Clin Oncol 23:8, 2004. e-Pub 2004.
169. Javle M, Khemka S, Donohue K, Demmy T, Han J, Nava H, Douglass H. Surgical resection in multimodality management of localized esophageal cancer improves outcome: a thirty-year experience. Gastrointestinal Cancer Symposium: Current Status and Future Directions for Prevention and Management. San Francisco, CA, January 22-24, 2004, 2004. e-Pub 2004.
170. Javle M, Khemka S, Donohue K, Demmy T, Han J, Nava H, Douglass H. Surgical resection in multimodality management of localized esophageal cancer improves outcome: a thirty-year experience. Proc Am Soc Clin Oncol 23:80, 2004. e-Pub 2004.
171. Gibbs JF, Sreekumar B, Hylander B, Walsh D, Driscoll D, Penetrante R, Repasky E, Javle M. Low incidence of EGFR and Her2/neu positivity in pancreatic cancer. Proc Am Soc Clin Oncol 23:134, 2004. e-Pub 2004.
172. Javle M, Fakih M, Zamboni WC, Ramnath N, Schwarz JK, French RA, Regal LL, Gorenflo RK, Creaven PJ. A phase I and pharmacokinetic (PK) study of weekly docetaxel (D), cisplatin (P), and daily capecitabine (C) (DPC) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 23:150, 2004. e-Pub 2004.
173. Wilkinson NW, Black JD, Roukhadze E, Driscoll D, Smiley S, Hoshi H, Geradts J, Javle M, Brattain M. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 8(4):Abstract 8, 2004. e-Pub 2004. PMID: 15120370.
174. Kim M, Tan D, Levea C, Yu J, Kuvshinoff B, Duttala S, Gibbs J, Javle M. Nuclear survivin expression correlates with poor prognosis in cholangiocarcinoma. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(14S):335 (abstr. 4092), 2004. e-Pub 2004.
175. Patt YZ, Lin E, Liebman J, Miller W, Lee F, Keiser W, Salvatore J, Diamandidis D, Eckhardt SG, Javle M, Justice GR. Capecitabine plus irinotecan: A highly active first-line treatment for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 23:271 (abstr. 3602), 2004. e-Pub 2004.
176. Hanna N, Chung T, Hecht JR, Vogel S, Rosemurgy A, Nemuniatis J, Javle M, Reid T, Chu K, Kessler P, Posner M, Chang K, Senzer N. Safety and efficacy of TNFerade in unresectable locally advanced pancreatic cancer: Results of the first two cohorts of a dose escalating study. Proc Am Soc Clin Oncol 23:204 (abstr. 3038), 2004. e-Pub 2004.
177. Hanna N, Chung T, Hecht JR, Vogel S, Rosemurgy A, Nemuniatis J, Javle M, Reid T, Chu K, Kessler P, Posner M, Chang K, Senzer N. Safety and efficacy of TNFerade in unresectable locally advanced pancreatic cancer (LAPC): Results of the first two cohorts of a dose escalating study. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(14S):Abstract 84, 2004. e-Pub 2004.
178. Patt YZ, Lin E, Leibmann J, Miller W, F-C L, Keiser W, Salvatore J, Diamandidis D, Eckhardt SG, Javle M, Justice GR. Capecitabine plus Irinotecan for chemotherapy-naive patients with metastatic colorectal cancer (MCRC). 2004 Gastrointestinal Cancer Symposium:Abstract 228, 2004. e-Pub 2004.
179. Gibbs JF, Sreekumar B, Hylander BL, Driscoll D, Penetrante R, Walsh D, Repasky EA, Javle M. MAP Kinase expression is independent of Her2/neu or EGFR expression in Pancreatic cancer. 2004 Gastrointestinal Cancer Symposium:Abstract 134, 2004. e-Pub 2004.
180. Senzer N, Chung T, Hecht JR, Vogel S, Rosemurgy A, Nemunaitis J, Javle M, Teid T, Chu K, Kessler P, Posner M, Chang K, Hanna N. Safety and efficacy of TNFerade in unresectable locally advanced pancreatic cancer (LAPC): Results of the first two cohorts of a dose escalating study. AACR/NCI/EORTC Molecular and Targets and Cancer Therapeutics conference, November 17-21, 2003, Boston, MA, 2003. e-Pub 2003.
181. Mortazavi, A, Shaukat A, Othman E, Kepner J, Fakih M, Walsh D, Smith J, Javle M. Role of annual computerized tomographic scans of the abdomen and pelvis (CT) for post-operative surveillance of patients (pts) with stage 2 and 3 colorectal cancer (CRC-2-3). Proc. Am Soc Clin Oncol 22:366 (abstr.1470), 2003. e-Pub 2003.
182. Beer TM, Javle M, Whitehouse MJ, Trump DL. Phase I study and pharmacokinetic (PK) evaluation of DN-101, a new formulation of Calcitriol. Proc Am Soc Clin Oncol 22:231 (abstr. 924), 2003. e-Pub 2003.
183. El Hajjar D, Javle M, Lawrence N, Khoudoud N, Fakih M, Rajput A, Donthireddy K, Groth J, Geradts J. Cyclooxygenase-2 (COX 2) expression before and after chemoradiotherapy in rectal cancer. Proc Am Soc Clin Oncol 22:377 (abst. 1516), 2003. e-Pub 2003.
184. Othman E, Ummadi S, BundyB, Yang G, Walsh D, Nava J, Gibbs J, Oleksowicz L, Javle M. Chemoradiation for elderly patients with esophageal cancer. Proc Am Soc Clin Oncol 22:370 (abstr.1487), 2003. e-Pub 2003.
185. Melnyk M, Yalamanchili R, Driscoll D, Kuvshinoff B, Fakih M, Javle M. Metastatic pancreatic cancer: A single institution experience with gemcitabine in combination with capecitabine. Proc Am Soc Clin Oncol 22:352 (abstr. 1412), 2003. e-Pub 2003.
186. Qureshi K, Leichman CG, Berdzik J, Muffley M, Fakih M, Smith PF, Melnyk M, Javle M. Incidence of hypersensitivity reactions to oxaliplatin (OXP) at Roswell Park Cancer Institute (RPCI) and protocol for desensitization. Proc Am Soc Clin Oncol 22:789 (abstr. 3173), 2003. e-Pub 2003.
187. Tripp P, Wilkinson N, Shaukat A, Gergel T, Russo R, Reinhart S, Spangenthal E, Javle M, Nava H, Yang G. Changes in cardiac function following neoadjuvant chemoradiation for esophageal cancer. Proc Am Soc Clin Oncol 22:367 (abstr 1472), 2003. e-Pub 2003.
188. Shaukat A, Mortazavi A, Demmy T, Yang G, Nava H, Kepner J, Javle M. Should preoperative endoscopy (EGD) be performed routinely for esophageal cancer patients (pts) after chemo-radiation treatment (CRT)?. Proc Am Soc Clin Oncol 22:365 (abstr. 1465), 2003. e-Pub 2003.
189. Donthireddy K, Wilkinson N, Lawrence D, Fakih M, Rajput A, Walsh D, Yang G, Javle M. Neoadjuvant chemoradiotherapy for rectal cancer: clinical experience and prognosis. Proc Am Soc Clin Oncol 22:365 (abst.1467), 2003. e-Pub 2003.

Book Chapters

1. Lee, S, Javle, M. Management of resectable and borderline resectable disease, 139-151, 2022.
2. Javadi, S, Fleming, JB, Javle, M, Lee, JH, Bhosale, PR. Cystic Pancreatic Lesions, 177-196, 2022.
3. Javle M. Pancreatic Cancer. In: MD Anderson Manual of Medical Oncology, 2014.
4. Javle M. Hepatobiliary Cancer. In: MD Anderson Manual of Medical Oncology, 2014.
5. Javle MM. Personalized therapy for pancreatic cancer. In: Principles of Molecular Diagnostics and Personalized Cancer Medicine, 2012.
6. Shroff R, Javle M, Wolff RA. Pancreatic Cancer. In: MD Anderson Cancer Handbook, 2010.
7. Javle MM, Fisch M. Overview of palliative management of pancreatic cancer. In: Handbook of Pancreatic Cancer, 2009.
8. Javle M, Varma G. Chemotherapy for palliation of pain: “about quality, not quantity”. In: Cancer Pain: Pharmacologic, Interventional, and Palliative Care, 2006.
9. Javle M, Raghavan D. Total androgen blockage for prostate cancer: the end does not justify the means. In: Genitourinary Tract Malignancies. Kluwer Academic Publishers, pp 201-210, 1996.

Letters to the Editor

1. Nelson, BE, Roszik, J, Ahmed, J, Barretto, CN, Nardo, M, Campbell, E, Johnson, A, Piha-Paul, SA, Glitza, IC, Weathers, S, Cabanillas, ME, Javle, M, Meric-Bernstam, F, Subbiah, V. RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers. Molecular cancer 23, 2024.